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A Tale of Two ARFs:  Tumor Suppressor and Anti-viral Functions of p14ARF 
Abstract 
 Animals have evolved complicated and overlapping mechanisms to guard against 
the development of cancer and infection by pathogenic organisms.  ARF, a potent tumor 
suppressor, positively regulates p53 by antagonizing p53’s negative regulator, MDM2, 
which in turn results in either apoptosis or cell cycle arrest. ARF also has p53-
independent tumor suppressor activity.   The CtBP transcriptional co-repressors promote 
cancer cell survival and migration/invasion. CtBP senses cellular metabolism via a 
regulatory dehydrogenase domain, and is a target for negative regulation by ARF.   ARF 
targets CtBP to the proteasome for degradation, which results in the up regulation of pro-
apoptotic BH3-only proteins, and p53-independent apoptosis.  CtBP inhibition by ARF 
also up regulates PTEN, reducing cancer cell motility, making CtBP a potential 
therapeutic target in human cancer. 
 The CtBP dehydrogenase substrate 4-methylthio-2-oxobutyric acid (MTOB) can 
act as a CtBP inhibitor at high concentrations, and is cytotoxic to cancer cells from a 
wide variety of tissues.   MTOB induced apoptosis was independent of p53, and 
correlated with the de-repression of the pro-apoptotic CtBP repression target Bik.  CtBP 
over-expression, or Bik silencing, rescued MTOB-induced cell death.  MTOB did not 
induce apoptosis in mouse embryonic fibroblasts (MEFs), but was increasingly cytotoxic 
to immortalized and transformed MEFs, suggesting that CtBP inhibition may provide a 
suitable therapeutic index for cancer therapy. 
  In human colon cancer cell peritoneal xenografts, MTOB treatment decreased 
tumor burden, and induced tumor cell apoptosis.  To verify the potential utility of CtBP  
as a therapeutic target in human cancer the expression of CtBP and its negative regulator  
  
 
xi 
ARF was studied in a series of resected human colon adenocarcinomas. CtBP and ARF 
levels were inversely-correlated, with elevated CtBP levels (compared with adjacent 
normal tissue) observed in greater than 60% of specimens, with ARF absent in nearly all 
specimens exhibiting elevated CtBP levels.  Targeting CtBP with a small molecule like 
MTOB may thus represent a useful and widely applicable therapeutic strategy in human 
malignancies.   
 ARF has long been known to respond to virally encoded oncogenes.  Recently, 
p14ARF was linked to the innate immune response to non-transforming viruses in mice.  
Therefore a wider role for the ARF pathway in viral infection was considered.  Previous 
studies linking p53 to multiple points of the Human Immunodeficiency Virus-1 (HIV-1) 
life cycle suggested that ARF may also play a role in the HIV life cycle.  In this study the 
interdependency of ARF and HIV infection was investigated.  ARF expression was 
determined for a variety of cell types upon HIV infection.  In every case, ARF levels 
exhibited dynamic changes upon HIV infection-in most cases ARF levels were reduced 
in infected cells.  The impact of ARF over-expression or silencing by RNAi on HIV 
infection was also examined.  Consistently, p24 levels were increased with ARF over-
expression, and decreased when ARF was silenced.  Thus ARF and HIV modulate each 
other, and ARF may paradoxically play a positive role in the HIV life cycle.   
 
 
 Chapter I 
Introduction 
Overview 
 Since the first single celled organisms arose more then a billion years ago a 
complex cellular system for interacting with and surviving in the surrounding 
environment has been evolving.  As single cell life gave way to more complex multi-
cellular organisms, cells evolved to cooperate and coordinate their activities for the 
benefit of the whole organism. Complex molecular programs evolved to control 
organismal development, ensuring appropriately timed and coordinated cell replication 
and specialization.  The inappropriate reactivation of many of these of same programs 
contributes to the initiation and progression of cancer (1).   
 The cellular response to external threats has also evolved as organisms grew more 
complex.  An innate, cell autonomous response to pathogens such as viruses and bacteria, 
preceded the addition of specialized immune cells that work together with the innate 
system to provide a complex immune response.  The evolution of the immune system has 
been mirrored by adaptation and evolution of pathogens (2-4).   
 There is considerable overlap at both the molecular and cellular levels between 
the pathways responsible for preventing cancer and infection.  In this thesis the role of the 
mammalian gene ARF in both tumor suppression and viral infection is considered.   
  
ARF and the INK4 Locus 
 The INK4/ARF locus encodes three distinct genes in mammals, INK4a, INK4b, 
and ARF.  INK4A and INK4B (also known as CDKN2A and 2B) both encode related  
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proteins, p16 and p15, that act as tumor suppressors by inhibiting cyclin dependent 
kinases CDK4/6, and causing cell cycle arrest (5). ARF results from the splicing of the   
unique first exon (exon 1β) onto exon 2 and 3 of INK4a, instead of exon1α (Figure 1.1) 
(6, 7).  The resulting gene is out of frame, so that an entirely unique protein is encoded by 
the alternate reading frame, hence p14ARF (p19ARF in mice).  ARF’s role as a tumor 
suppressor depends on its ability to inhibit the E3 ligase activity of the proto-oncogene 
HDM2 (MDM2 in mice), and this inhibition stabilizes and activates the p53 tumor 
suppressor (8-10).  Therefore the INK4/ARF locus constitutes a potent collection of 
tumor suppressors likely to be targeted by oncogenic processes. 
 
Evolution of the INK4/ARF Locus 
 Ink4b is the oldest of the genes, having a homologue in fish, while INK4a and 
ARF are first seen in birds, with only exon 1β being translated, forming a functional 
p7ARF. In birds exon 1α is not present at all, likely due to its loss in a partial duplication 
of exon1β (11), with INK4B exhibiting most of the functions of INK4A.  Despite the 
lack of translation of exon 2 in birds and early studies localizing ARF essential functions 
to exon 1β, a detailed study of the evolution of the Ink4a/ARF locus suggests that it is 
unlikely exon 2 is without function (12).  In order to determine the likelyhood of 
conserving the INK4A reading frame and the ARF reading frame, a simulation of one 
million exon 2 sequences that kept the amino acid sequence of p16INK4a intact only 
  
 
 
 
        
Figure 1.1: The INK4b/ARF/INK4a Locus.  The locus consists of three tumor suppressor 
genes. Exons are indicated by letter E and colored rectangles and the promoters of the genes are 
designated by arrows. ARF is encoded by Exon1β, 2 and 3 with alternate reading frame in 
exon2. Both INK (INK4a and INK4b) genes encode inhibitors of cyclin D-dependent kinases 
CDK4 and CDK6 (p16INK4a and p15INK4b respectively). The locus structure in mammals, birds, 
and fish is below. 
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produced 4% that did not insert a premature stop codon into the ARF reading frame, 
suggesting it is not just by chance that ARF has not been truncated in evolution.  Further 
analysis showed that ARF and Ink4a are evolving rapidly and asymmetrically, with ARF 
accumulating non-synonymous changes 10-100 times more rapidly then Ink4a.  This is 
unusual and seemingly deleterious for a locus concerned with multiple tumor suppressor 
networks, and will be revisited in the context of other ARF activities. 
 
The INK4/ARF locus in cancer 
 The role of the genes encoded by the locus in responding to and inhibiting excess 
proliferation and inappropriate survival makes them a clear target for inactivation in 
neoplastic disease.  Several methods of inactivation have been reported, including 
homozygous deletion, which is observed in approximately 14% of all human tumors (13).  
Mutations within the two genes are observed in 5% of human tumors, especially point 
mutations in the shared second exon (14).  Promoter silencing by methylation, has been 
found in about 19% of human tumors (14, 15).  However dissecting the relative 
contribution of each member of the INK4/ARF locus to tumor suppression in humans has 
been difficult.  Murine models have been more useful for delineating differences, though 
the relevance to the human locus remains unclear. 
The specific functions of ARF and INK4a in preventing tumorigenesis have been 
studied through the generation of knockout models (16). Mice deficient for both p16INK4a 
and p19Arf were generated by disruption of the shared exons 2 and 3 of the INK4a locus. 
Consistent with the fact that the INK4a/ARF locus encodes two tumor suppressors, 69% 
of double-null mice developed spontaneous fibrosarcomas and lymphomas. Specific 
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p19Arf-/- mice were then created by targeting exon1β, and 80%  spontaneously developed 
malignant tumors, predominantly lymphomas and sarcomas. Additionally, p19Arf-/- MEFs 
demonstrated increased proliferation and susceptibility to H-ras mediated transformation 
(17, 18). In contrast, MEFs derived from mice with targeted p16 mutation (deletion of 
exon 1α), did not exhibit increased immortalization or susceptibility to 
transformation(17, 19). However, 25% of p16Ink4a-/- mice did develop tumors, including 
soft tissue sarcomas, spleenic lymphomas and melanomas, though their incidence 
increases with mitogen treatment (19), suggesting ARF plays a greater tumor supressor 
role then p16INK4a in murine tumor suppression. 
 Regulation of the locus’ expression is markedly different in mice and humans. 
While both ARF and p16 are up regulated in response to senescence and 
mitogenic/oncogenic signaling in mice, they are activated by different stimuli in human 
cells.  For example, DNA damage and activated Ras induces p16, but not ARF in human 
cells (18, 20-22), while ARF is activated in response to oncogenes such as E1A, E2F1, 
and MYC (23-25).  Expression from the locus is tightly controlled by complex and still 
not fully understood group of repressors, preventing the activation of p16INK4A  and 
ARF in response to normal fluctuations of pro-growth signals during non-pathological 
cell cycle progression.  Global suppression of the locus is linked to BMI-1(26, 27), and 
the polycomb group proteins CBX2, and CBX7 (21).  In addition, transcriptional 
suppression of the entire locus has been linked, through CDC6, to an origin of DNA 
replication initiation just upstream of Ink4b (28).  
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The p53 dependent and independent activities of ARF 
 In spite of these differences, ARF functions as a tumor suppressor in humans as it 
is targeted for inactivation by chromosomal deletion, intragenic mutation, or 
transcriptional silencing by promoter methylation (29).  ARF inactivation phenocopies 
p53 loss in tumors, identifying ARF loss as an alternative route to p53 inactivation (30).  
Upon induction, ARF stabilizes p53 by inhibiting the E3 ligase activity of MDM2, 
sequestering MDM2 in the nucleolus, and by preventing MDM2-mediated nuclear export 
of p53 and subsequent degradation of p53 in the cytoplasm (31). Stabilization of p53 
leads to the activation of p53 transcriptional target genes, and results in either cell cycle 
arrest or apoptosis (9) (Figure 1.2).  Loss of ARF desensitizes cells to the constitutive 
oncogenic signaling, such as over expression of c-myc, v-abl, E2F or loss of Rb, allowing 
deregulation of the cell cell cycle and inappropriate survival (23, 24, 32-34). 
 In the absence of p53, ARF levels are significantly elevated (7), though  
reintroduction of wild type p53 into p53 null-cells can restore ARF levels to normal, 
suggesting a negative feedback loop between ARF and p53 in vivo (35). Biochemical 
analysis of the ARF/MDM-2 interaction has identified two distinct binding sites in the N-
terminal domain of ARF that interact with the central acidic domain of MDM2 (36-38).  
The ARF/MDM2 interaction constitutes a form of binding uncovered in important 
cellular signaling pathways, where one or more of the interacting domains are 
intrinsically disordered prior to binding (39).  Upon binding, the interaction induces and 
stabilizes ordered structure.  This mode of binding appears to be important in other tumor  
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Figure 1.2:  The p53 dependent functions of ARF.  Mitogenic signals acting through Ras stimulate 
phosphorylation of Rb, interrupting its interaction with E2Fs and promoting S phase entry. Upon oncogenic 
stress, ARF gets activated and interferes with the activity of MDM2, preventing ubiquitination and 
cytoplasmic export where it is degraded by the proteasome. Activated p53 turns on the p53-dependent 
transcriptional program by regulating several target genes to induce either cell cycle arrest or apoptosis in a 
context dependent manner. In addition to directly activating p53, oncogenic stress can also activate protective 
DNA damage response. Depending on the signal, DNA-damage responses activate the kinases ATM or ATR 
and these kinases phosphorylate p53 directly or through CHK kinases and these phosphorylations activate 
transcriptional activity of p53. 
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suppressor-oncogene interactions, such as p27 binding of CDK2/Cyclin A complexes 
(40-43). 
 Further evidence of ARF’s role in suppressing cancer in humans can be found in 
studies of familial inheritance of cancer risk. Familial inheritance of cancer-prone 
mutations in this locus has more often been associated with p16 then ARF (44).  
However, mutations targeting exon1β specifically have now been found in more then 20 
different pedigrees, with a wide array of associated phenotypes (45-52). Malignancies in 
tissues including melanoma, breast, pancreas, and the central nervous system have been 
linked to ARF-specific mutations.  Missense, splicing alterations, and deletion mutations 
have all been described (45-52).  While very few missense mutations have been 
described, until recently they had all clustered in the MDM2 binding domain of ARF, and 
thus presumably related to p53-dependent activities of ARF.  However, a recent report 
has identified a familial melanoma cohort that carries a point mutation outside of the 
MDM2 binding domain, where the highly conserved arginine 55 is mutated to histidine 
(49).  This region has been demonstrated to be unimportant for ARF’s interaction with 
MDM2, and moreover it is implicated in ARF mediated degradation of the proto-
oncogene C-terminal binding protein (CtBP).  Thus this cohort provides the first potential 
direct evidence of p53-independent activities of ARF in human cancer.   
 The first evidence that there might be any role for ARF in tumor suppression 
outside of the p53 pathway came from mouse knockout studies.  Animals lacking p53 
and MDM2, ARF and p53, or all three genes, triple knock out or TKO mice, were found 
to have no significant difference in survival, but mice lacking ARF, p53, and MDM2 
exhibited twice the rate of multiple primary tumors compared to mice retaining MDM2, 
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with several developing tumors from three distinct cell lineages (53). In addition to a 
greater frequency of multiple tumors, mice with combined loss of ARF and either p53, or  
MDM2 have tumors arising from epithelial tissues of origin, and tumors arising from 
epithelial tissues are rare in p53 knockout mice. However, ARF knockout mice developed 
epithelial tumors 12%-28% of the time (18, 44).  Combined loss of p53, ARF and/or 
MDM2, resulted in a substantially increased incidence of epithelial cancers, including 
intestinal, renal cell, and hepatocellular carcinomas not previously observed in ARF null 
animals (53, 54). ARF retention in the absence of both p53 and MDM2 leads to the 
development of primarily mesenchymal tumors, phenocopying p53 knockout mice (53, 
55).  
 To test if ARF could block proliferation in the absence of p53 and MDM2, MEFs 
from TKO mice were infected with retroviruses encoding ARF or a mutant ARF lacking 
the MDM2 binding domain. ARF was able to induce a G1/G2 cell cycle arrest in the 
absence of p53 and MDM2, blocking BrdU incorporation almost entirely.  Surprisingly, 
mutant ARF, lacking the MDM2 binding domain, was also able to block proliferation, 
though to a lesser extent, suggesting that there are additional functional domains in ARF 
responsible for inhibiting proliferation (53).   
 Several other lines of evidence have emerged supporting the hypothesis of p53 
independent ARF tumor suppression. Simultaneous inactivation of p53 and ARF in 
certain human tumors clearly suggests a role for ARF outside of the 53 pathway.(56)  
Evidence has emerged that ARF controls senescence in melanocytes independent of p53 
(57).   ARF loss also predisposed mice to melenoma formation, whereas p53 loss did not 
(57).   Furthermore, ARF loss accelerates pituitary tumorigenesis in Rb haplo-insufficient 
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mice, and p53 loss suprisingly has no affect (58).  Additionally, in a transgenic K-ras skin 
cancer model, ARF loss accelerated tumor growth in a p53-independent manner (59).  
Finally the ARF null mice were discovered to go blind shortly after birth, due to  p53 and 
MDM2 independent down regulation of PDGF expression in the perivascular cells of the 
vitreous.  Without this activity these cells proliferate in an uncontrolled fashion, 
preventing the regression of the hyaloid vascular system, and causing eventual 
irreversible damage to the lens and retina (60). This finding provides the first evidence of 
a role for ARF in the normal development of any tissue or organ.     
 Taken together, these lines of evidence strongly support the hypothesis that ARF 
serves a function outside of its MDM2 inhibition and stabilization of p53.  Attempts to 
elucidate the mechanism of this activity have resulted in the discovery of dozens of new 
ARF interacting proteins (61-64).  Validation of these interactions and their significance 
has been hampered by the many inherent difficulties of working with ARF in vitro 
(Figure 1.4).  ARF is highly basic, containing 20% arginine, conferring on it an 
isoelectric point greater then 12.  The amino acid sequence of ARF in animals shows 
great variation, making it difficult to compare bio-physical data between species.  Only 
six amino acids are conserved in exon 1β between chickens and humans, though the 
sequence difference between humans and primates is very small (65).   
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Figure 1.3:  Amino acid sequence and conservation of the ARF Exon1β . The amino acid 
sequence of Exon 1β encoded region from birds and mammals is shown. MDM2 binding (2-14 
residues) and CtBP2 binding (37-51) and all conserved residues including L46D are indicated in Red. 
Arginine residues are indicated in blue. 
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ARF is principally nucleolar in its cellular localization with reports of small functionally 
related pools in the nucleus, cytoplasm and mitochondria (37, 66, 67).  It is a naturally 
lysine-less protein that is none the less ubiquitinated at its N-terminus by the N-end rule 
pathway (68).  This ubiquitination and degradation has been linked to transcriptionally 
independent regulation of ARF by the oncogene c-Myc (69). ARF also contains an 
internal translation start site that produces a smaller form of ARF (in frame) with unique 
properties and functions (70).  All of these properties make it difficult to dissect out the 
contributions of relatively small amino acid sequences to ARF’s function.  Further 
complicating these structure/function studies is emerging data suggesting that ARF plays 
a role in diverse cellular functions relating to viral infection, oxidative stress related to 
aging, and cardiovascular disease (71-73).    
 ARF’s p53-independent activities are outlined in Figure 1.4.  ARF has been 
shown to block cell cycle progression and and cancer cell proliferation through its 
interactions with two known oncogenes, Myc and members of the E2F family.  ARF  
interacts with both c-Myc and N-myc, inhibiting Myc transcriptional activation of targets 
important for proliferation (74-76).  The precise mechanism of inhibition has not been 
fully elucidated, and it is unclear whether ARF alone is sufficient to inhibit Myc 
mediated transcription, or if  NPM is also required (77).  ARF may have additional 
affects on Myc that depend on p53 and the ubiquitin ligase ARF-BP1(77, 78).  
Interestingly Myc has recently been shown to inhibit the newly discovered ubiquitin 
ligase for ARF, Ulf, which suggests a transcription independent mechanism for Myc 
activation of the ARF pathway (69).   
  
 
 
      
  
 
Figure 1.4:  p53-independent functions of ARF. ARF’s tumor suppressor functions independent 
of p53 have been connected to interactions with novel binding partners, such as those indicated 
below.  ARF interaction results in the inhibition of binding partner activity by degradation, re-
localization, or competition for limited binding sites.  
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 As opposed to Myc regulation, ARF inhibition of E2F is both direct and indirect.  
ARF is able to target E2F1, 2, and 3 for proteasome dependent degradation (79).  ARF 
also inhibits transcriptional repression by the E2F/DP1 complex by binding DP1 and 
preventing the complex from forming (80, 81). In the case of E2F4/DP1, this results in up 
regulation of the nucleotide excision repair protein, XPC, independent of p53 (80). 
 While ARF regulation of Myc and E2F contribute to its block on cell cycle 
progression, ARF’s nucleolar activities have been linked to regulation of other processes 
necessary for cell growth. ARF has been shown to interact with the nucleolar protein 
Nucleophosmin (NPM).  ARF forms a stoichiometric complex with NPM, disrupting 
ribosome biogenesis and slowing progression of cells through the growth phases of the 
cell cycle (82-84).  This interaction is also responsible for ARF’s nucleolar localization 
(82).  Doubts have been cast on the ability of physiologic levels of ARF to inhibit NPM, 
which is expressed in substantial excess to ARF under most conditions (63).  However it 
has been demonstrated that NPM regulates ARF stability (85) and negatively impacts 
ARF’s ability to inhibit Myc activity independent of p53 (77).  More interestingly a 
cytoplasmicly retained mutant NPM found in patients with acute myeloid leuekemia 
causes ARF to be exported to the cytoplasm and degraded, and is capable of transforming  
MEF’s in the presence of E1A (86).  Taken as a whole, it is clear that ARF/NPM 
interaction is important for cell growth and survival in a mechanism that does not require 
p53.   
 ARF is not directly induced by DNA-damage, though ARF loss impairs the DNA-
damage response indirectly, through its effects on Mdm2 and p53 (87). ARF is reported 
to activate both ATM and ATR in cells lacking p53, and upon ARF expression, human  
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lung adenocarcinoma cells arrested only in G2 phase (88). ARF activates ATM/ATR by 
interacting with and stabilizing TIP60, which induces acetylation of ATM(89).   DNA 
damage also causes a transient translocation of ARF from the nucleolus to the nucleus 
and cytoplasm 
 The p19ARF mRNA encodes a second protein, termed short mitochondrial ARF 
(smARF) that localizes to the proteinsase K resistant compartment of the mitochondria.   
smARF is translated from an internal translational initiation site at methionine 48 in 
human and 45 in mouse (70).  smARF has been reported to induce autophagic cell death 
by altering the mitochondrial membrane potential in a p53-independent and Bcl-2 family 
member independent fashion (70).  ARF induced autophagy appears to be context 
dependent because ARF mediated autophagy appears to be at least partially p53 
dependent (90).  Further complicating these results are reports that full length ARF can 
induce autophagy through inhibition of Bcl-xL/Beclin complex formation (91), and 
induce mitochondrial dependent apoptosis through its interaction with the mitochondrial 
protein p32 (67).  Further studies are required to determine the relative contribution of 
each of these activities to ARF’s overall role in promoting cell death.  
 Work in the Grossman lab has focused on identifying the mechanism of ARF 
induced apoptosis independent of p53.   A yeast two hybrid screen, with mouse Arf as 
bait, identified the transcriptional regulator C-terminal Binding Protein (CtBP) (92).  
ARF and CtBP were shown to interact both in vitro and in vivo through a novel 
hydrophobic binding site at the C-terminal end of exon 1β.  ARF promotes proteasome 
dependent degradation of CtBP, without affecting CtBP ubiquitination.  A point mutation 
in ARF’s CtBP binding domain specifically abrogates CtBP binding (L46D in mice, 
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L50D in humans).  Expression of ARF in ARF null-p53 null HCT116 colon 
adenocarcinoma cells resulted in CtBP dependent apoptosis.  Furthermore, expression of 
the CtBP binding deficient mutant, ARF L50D, failed to induce CtBP degradation or 
apoptosis.   
 Further study of ARF-CtBP mediated apoptosis revealed that either the down 
regulation of CtBP or the exogenous expression of ARF up regulated the BH3-only pro-
apoptotic protein BIK (93).  CtBP, through its interaction with the transcription factor 
basic Krüppel-like factor (BKLF) binds to the BIK promoter and represses its 
transcription.  siRNA targeting either CtBP or BKLF, or ARF over-expression resulted in 
the de-repression of Bik expression, and Bik-mediated apoptosis. There is evidence that 
CtBP repression of BH3-only proteins will be tissue and context dependent (93).  ARF 
mediated degradation of CtBP also impairs cancer cell motility, especially in the setting 
of hypoxia (94, 95).  Both the anti-apoptotic and pro migration/invasion properties of 
CtBP suggest it to be an oncogene, and possibly an excellent target for therapy in  
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     Figure 1.5: The ARF-CtBP Pathway. It has been demonstrated that the C-terminal Binding Protein 
(CtBP) promotes cancer cell survival and migration through repression of various transcriptional targets, 
including the BH3 only protein BIK.  Multiple tumor suppressors including p14ARF target CtBP for 
degradation.  Down regulation of CtBP by RNAi or ARF induces apoptosis and inhibits migration, making 
CtBP an attractive target for cancer therapy. 
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neoplastic disease.  CtBP’s mechanism of action and cellular functions, both physiologic 
and pathologic, will be outlined further 
 
C-terminal Binding Proteins  
 The C-terminal binding protein (CtBP) family proteins are conserved from 
invertebrates to humans, with homologues in both of the model organisms C. elegans and  
D. melanogaster. In vertebrates, the gene is duplicated, and two genes, CtBP1 and 
CtBP2, are expressed widely both during development and in adult tissue (96, 97). CtBP1 
was first identified as a protein bound to the C-terminal region of adenovirus E1A 
oncoprotein (98).  Mutational analysis revealed a five amino acid motif, PLDLS, 
conserved at the C-terminus of E1A that was required for CtBP binding (99).  This CtBP 
interaction influences the ability of E1a to transform cells in the presence and absence of 
co-activating oncogenes.  Further studies revealed the ability of CtBP to interact with 
other viral oncoproteins encoded by the Epstein Bar Virus, EBNA3A, and EBNA3C, the 
latter requiring CtBP binding for co-transformation with activated Ras (100, 101).  
CtBP’s normal function as a transcriptional co-repressor was uncovered later through its 
interactions with the DNA binding transcription factors Knirps, Kruppel, Snail, and Hairy 
(102, 103) 
 CtBP proteins encode an NAD+/NADH-dependent dehydrogenase domain that is 
homologous to D-isomer specific 2-hydroxy acid dehydrogenases (D2-HDH) (Figure 1.6) 
(104).  The dehydrogenase activity appears to be unnecessary for transcriptional  
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Figure 1.6:  Organization and structure of CtBP.  Functionally characterized domains of CtBPs. PLDLS-
binding motif is necessary for interacting with DNA sequence specific transcription factors, and other 
transcription factors. The NADH binding, dimerization, and catalytic domain, including the REH triad. CtBPs 
nuclear localization is regulated by acetylation of K6, 8, 10 residues by p300.  Protein stability negatively 
regulated by C-termianl phophorylation.  Crystal structure of CtBP1 in complex with NADH, along with 
crystallographic dime, NADH binding sites circled in yellow.   
 
 
 
Adopted and modified 
from Chinnadurai 2007,  
Kumar et al., 2002 
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regulation, and thus its in vivo significance remains unknown (105). NADH binding, 
however, is involved in CtBP oligomerization (106, 107). 
 In the presence of NADH, CtBP undergoes conformational changes that promote 
its hetero- or homo-dimerization.   This structural change was accompanied by increased  
CtBP binding to PLDLS containing transcription factors, allowing the formation of core 
transcription repression complex (106, 108-111). CtBP’s activity is sensitive to the 
cellular redox state and it has 100 times greater affinity for NADH than NAD+. (107). 
The C-terminal domain of CtBP, unlike the core dehydrogenase domain, has been 
refractory to structural studies.  It is predicted to be disordered, and behaves as such in 
bio-physical assays (112).  This disordered domain is responsible for posttranslational 
regulation of CtBP activity and stability, and the site of interaction with ARF (92, 113).  
 The N-termini of CtBP proteins are involved in the regulation of CtBP 
intracellular localization.  CtBP1 is found throughout the cell, with the exception of an 
isoform lacking the N-terminal 20 amino acids, called CtBP3/BARS, which is involved 
in regulation of the Golgi complex (114).  CtBP2 is almost entirely nuclear in its 
distribution, and its localization is dictated by acetylation of N-terminal lysines by p300 
(115, 116). In addition to CtBP2, an N-terminal splice variant, under the control of a 
separate promoter, encodes a gene called RIBEYE involved in synaptic ribbon formation 
in the central nervous system (117, 118).  Through duplication, differential splicing and 
transcriptional control, the CtBP genes are able to perform a multitude of functions in the 
cell.  The focus of this dissertation involves the transcriptional repressor function of 
CtBPs.   
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CtBPs as Transcriptional repressors 
 CtBPs function predominantly as transcriptional corepressors in the nucleus in 
conjunction with a number of different DNA-binding repressors. Initial studies with 
dCtBP in Drosophila embryos provided strong evidence for its role in transcriptional 
repression (119). Based on studies involving embryos deficient in maternal dCtBP, and 
transgenic embryos containing repressors with CtBP-binding mutants, a number of 
Drosophila repressors were identified which utilize dCtBP as a corepressor. The 
repressors such as Krüppel, Knirps, Snail, Giant, Hairy and Groucho, all require dCtBP 
for exerting their full repressive function during embryonic development (102, 103, 119, 
120). 
CtBPs act as a transcriptional co-repressor through its PLDLS dependent 
interaction with DNA-binding core repressors, such as BLKF, ZNF217, and ZEB, 
suggesting that CtBP functions principally as a corepressor (121, 122).  Thus far, more 
than thirty different transcription factors have been suggested to exert their function 
through recruitment of  CtBP (109).  The C. elegans homologue, ceCtBP, directly binds 
DNA through its N-terminal thanatos-associated protein (THAP) Zn2+ finger domain 
(123).  Separating the repressor function and DNA binding function has allowed CtBP to 
evolve and target a larger number of genes, utilizing the sequence specificity of many 
different co-repressors. 
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         Figure 1.7:  CtBP recruitment of transcriptional repressor machinery.  CtBPs recruit core 
repressors and other factors associated with histone modification through PLDLS-binding clefts.   
These include histone deacetylases as well as histone methyl transferases.  Complexes are targeted to 
particular genes through sequence specific DNA binding, PLDLS motif containing transcription 
factors, such as Znf217.  Post-translational modification such as phosphorylation and sumoylation may 
regulate the stability of this complex. 
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 Much progress has been made in elucidating the mechanisms of CtBP mediated 
transcription repression. CtBP repressor complexes are postulated to be targeted to a 
particular locus through the PLDLS dependent interaction with DNA binding 
transcription factors.  Competitive binding to this site by E1A can inhibit transcriptional 
repression(124).  NADH bound dimeric CtBP is then able to recruit multiple types of 
repressor complexes including class 1 and class 2 histone deacetylases (HDACs), and the 
CoRest complex (110).  CtBPs can also repress transcription in an HDAC independent 
fashion (125). CtBPs are reported to play a direct role in repression mediated by 
polycomb group (PcG) proteins YY1 and HPC2 in mammals, which repress transcription 
by diverse mechanisms including chromatin compaction as well as physical occupation 
of target promoters (126-128).   
It should be noted that there is emerging evidence that CtBP can also act as a 
transcriptional activator.  dCtBP functions as a transcriptional activator when over 
expressed in different mammalian cells , but only when  tethered with Gal4 (129). 
CtBP2-null mouse embryos revealed that one of the target genes of Wnt3A, Brachyury 
was transcriptionally repressed compared to wild-type embryos.  This effect appears to be 
indirect given the absence of direct evidence for CtBP binding and activating the 
promoter.  Loss of CtBP activity resulting in the de-repression of an activator, or 
inhibition of a directly acting repressor is a more likely explanation. Tcf3 represses 
Brachyury through the corepressor Gro, which contains two CtBP binding motifs.  It is 
possible that CtBP manifests its coactivator function by interfering with the repressor 
function of Gro. More recently, CtBP was identified as a transcriptional activator of the 
multi-drug resistance transporter (MDR1; Pg-p) (130).  CtBP was found to bind directly  
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to the MDR1 promoter by both ChIP and electrophoretic mobility shift assay (EMSA).  
This binding resulted in a nearly four fold increase in MDR1 expression, and RNAi 
depletion of CtBP induced chemotherapy sensitivity in multiple chemo resistant cell 
lines.  It is therefore likely that further examples of CtBP functioning, as an activator will 
be discovered, and determination of the mechanism, and how it differs from repression, 
will be key to understanding CtBP’s overall role in transcription regulation.   
 
CtBPs in normal development and tumorigenesis 
 Investigations into CtBP’s cellular functions have revealed an important role for 
these genes throughout evolution.  Inactivation of the dCtBP gene is lethal in Drosophila 
(103).  Progressive segmentation defects were observed with reduced levels of maternal 
dCtBP, which has been attributed to defects in the transcriptional repressor functions of 
Snail, Knirps, and Hairy. CtBPs also play a critical role in the development of Xenopus 
embryos (131-133), and the role of CtBP in avian development consists of both 
overlapping and tissue specific functions for CtBP1 and CtBP2 (134). CtBP has also been 
linked to a human developmental disorder, with a mutant form of the CtBP binding 
protein TGIF that is unable to bind CtBP, resulting in holoprosencephaly (135).    
 While its role in worm development is not yet clear, CtBP is known to regulate 
lipid metabolism, and subsequently controls life span in C.elegans (136).  Loss of CtBP 
results in prolonged lifespan, dependent upon the expression of the lipase Lips7.  CtBP 
has also been shown to regulate SirtT1, the human homolouge of the aging related gene  
Sir2 in worms (137).  Whether CtBP’s role in aging is evolutionarily conserved, remains 
unknown.   
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 Genetic studies in murine models have furthered understanding of the normal role 
CtBP’s play in organismal development.  Generation of mice lacking one or both CtBP 
genes has revealed wide spread expression of both proteins, with both distinct and 
overlapping functions (97). CtBP1-null mice are viable and fertile, but 30% smaller then 
wildtype or heterozygous mice, and 23% die within the first twenty days post partum.  
CtBP2-null suffer embryonic lethality between E9 and E 10.5. The lethality in CtBP2-
null mice was primarily due to vascular defects in the placenta, but there were also 
marked differences in limb, neural, and heart development, compared to heterozygous 
and wildtype litter mates.  At least some of these defects appear to be related to a function 
for CtBP in the Wnt pathway, with decreased CtBP dependent activation of the Wnt3a 
target Brachyury.  CtBP1 and CtBP2 functions were further studied by generating It is 
combinations of CtBP1 and CtBP2 deletion. Mice heterozygous for both CtBP1 and 
CtBP2 were viable and fertile, resembling the phenotype of CtBP1 null mice, being both 
smaller and less robust. Mice that were CtBP1-/-  CtBP2 +/- and CtBP1+/- CtBP2-/-  
were both embryonic lethal, with expanded developmental defects in the nervous, 
vascular, and musculoskeltal systems (97).  It is therefore clear that any chemical 
inhibitor of CtBP activity would likely be teratogenic.  The exact degree of overlap in 
function of CtBP1 and CtBP2, as well as post-embryonic roles for both genes remains 
unclear.  Conditional and tissue specific knock-in/knock-out mice would help to advance 
our understanding of normal CtBP function, as well its role in pathologic processes.  
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CtBP and Tumorigenesis 
There is mounting evidence that CtBP significantly contributes to the oncogenic 
phenotype of cancer cells.  Its involvement in cellular transformation, cancer cell 
survival, and motility, extend well beyond its role in p53-independent apoptosis mediated 
by ARF (Figue 1.5).  As a metabolically sensitive repressor, CtBP activity is likely 
augmented and unique in the hypoxic tumor microenvironment, making it an excellent 
target for anti-cancer therapy.  CtBP’s functions in cancer cell survival, epithelial to 
mesenchymal transition (EMT), invasion/metastases, and its antagonism of and by 
cellular tumor suppressors will be reviewed (Figure 1.8).   
CtBP’s role in EMT 
 Down regulation of epithelial markers is a hallmark of EMT. EMT contributes to 
tumor cell survival in the absence of cell adhesion, and increases the motile and invasive 
potential of these cells, promoting tumor metastases.  Inhibition of CtBP activity by E1A   
resulted in the up-regulation of multiple epithelial cell adhesion molecules, including E-
cadherin, deomglein-2, and plakoglobin (138).  These genes were unaffected by E1A 
mutants unable to bind CtBP.  These results shed light on how inhibition ofCtBP was 
able to block E1A transformation via the epithelialization of cells, thus establishing CtBP 
as an antagonist of the epithelial phenotype (139-141).   This is also consistent with the 
role of CtBP in repression of several genes important for conferring epithelial phenotype, 
such as E-cadherin (142).  
CtBP binding partner and transcriptional repressor Zeb1, is over expressed in human 
cancer, and is a negative regulator of E-cadherin (143, 144). Gene expression studies in 
MEFs from CtBP knockout animals linked the loss of CtBP with up regulation of 
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multiple epithelial markers including E-cadherin and kertain-8 (139, 142).  Other studies 
have shown CtBP repression of E-cadherin to be increased under hypoxic conditions, 
resulting in greater cancer cell motitliy (113, 145).  ARF has been demonstrated to reduce 
cancer cell motitlity through its degradation of CtBP and subsequent upregulation of 
PTEN in normoxic, and to a greater degree, in hypoxic conditions (94, 95). Overall these 
data suggest CtBP is well suited to modulate the aggressiveness of cancer cells under 
conditions found in vivo. 
 
CtBP as an anti-apoptotic protein 
 Analysis of CtBP1/2 deficient cells has revealed CtBPs to be pro-survival genes.  
MEFs from CtBP-null embryos were hypersensitive to apoptosis in response to different 
stresses such as anoikis, the death receptor ligand Fas, and genotoxic agents (139, 142).  
Microarray gene expression analysis of CtBP null MEFs as compared to heterozygous 
and wild type MEFs revealed the CtBP dependent repression of pro-apoptotic genes 
including PTEN, insulin-like growth factor binding proteins, Bax, Noxa, PERP (p53-
effector related to pmp-22), and Id-1(142).    CtBP depletion by RNAi in human tumor 
cell lines was sufficient to induce apoptosis without any additional stress (113).  
Inhibition of CtBP by RNAi or ARF over expression induced apoptosis through induction 
of the BH3-only protein BIK (92, 93).  CtBP also directly suppressed p53 target gene 
transcription such as Bax, through its interaction with Mdm2, and can thus regulate p53- 
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Figure 1.8:  CtBP antagonism of tumor suppressor pathways.  Hypoxic conditions of the tumor 
microenvironment increase the cellular NADH/NAD+ ratio, increasing CtBP activity.  CtBP inhibits 
expression of the cyclin dependent kinase inhibitors INK4a and INK4b, disrupting cell cycle arrest and 
senescence. CtBP activation also initiates EMT through the repression of multiple epithelial markers, such as 
E-cadherin. Repression of pro-apoptotic proteins, such as BIK, allow cancer cell survival despite stress and 
apoptogenic signaling.  These CtBP functions are opposed by a number of tumor suppressors including APC, 
HIPK2, and ARF.   
 
 
 
 
 
ARF 
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dependent apoptosis (146). CtBPs are reported to associate with the Evi-1 repressor, 
which is a negative regulator of TGF-β signaling, and contributes to the progression of 
leukemias by inhibiting apoptosis (147). CtBP has also been shown to maintain 
mitochondrial function during glucose deprivation, through its repression of Bax (148).  
Most recently CtBP has been identified as co-repressor, through BKLF binding, of the 
pro-apoptotic BH3-only gene Bik. Inhibition of CtBP by RNAi or ARF over expression 
induced apoptosis through induction of BIK in human colon cancer cells (92, 93).  Thus, 
CtBP is a robust pro-survival protein in both normal and neoplastic tissues, and is 
therefore presumably well suited to initiate and/or sustain tumorigenesis. 
CtBP: Fighting tumor suppressors on both sides 
 In addition to its roles in promoting survival and EMT, evidence for CtBP’s role 
in human cancer lies in its entanglement with multiple tumor suppressors.  Exposure to 
UV-radiation activates homeodomain interacting protein kinase 2 (HIPK2), promoting 
phosphorylation of the C-terminal domain of CtBP, and targeting of CtBP for ubiquitin-
dependent degradation by the proteasome (113, 149).  Phosphorylation of Serine 428 in 
CtBP2 appears to be necessary for ARF mediated degradation, suggesting HIPK2 is 
responsible for modulating CtBP ubiquitination, while ARF controls delivery to the 
proteasome (personal communication R. Kovi)  
 The adenomatous polyposis coli (APC) tumor suppressor has been well 
characterized as a negative regulator of the Wnt and β-catenin pathways. Two reports 
have now provided compelling evidence that APC targets CtBP for degradation (150, 
151).  Silencing of APC in human cancer cell lines up-regulated CtBP protein levels, 
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repressing components of the retinoic acid pathway necessary for intestinal 
differentiation (150).  Adenomas from patients with familial adenomatous polyposis 
showed increased levels of CtBP protein, but not RNA, suggesting that APC controls 
CtBP stability in vivo, and that APC loss contributes to tumorigenesis through 
deregulation of CtBP as well as β-catenin.  Further study of this interaction in a zebra fish 
model showed that APC loss was insufficient for nuclear localization and activation of β-
catenin, which required additional activation of KRAS.  However APC loss was 
sufficient to activate the CtBP mediated loss of intestinal differentiation and adenoma 
formation, implicating CtBP up-regulation may be an initiating event in colon cancer.  
These results were supported by a qualitative study of human samples showing increased 
expression of CtBP in adenoma and carcinoma samples, compared to uninvolved 
adjacent tissue.  
 The interaction between CtBP and the ARF tumor suppressor has already been 
described, but recent studies would indicate that CtBP has a more complex relationship 
with the INK4A/INK4B locus. CtBP represses both p16INK4a and p15INK4b, but not 
p14ARF mRNA expression (152-154).  CtBP repression of p16INK4a relieves 
senescence in primary human cells, and is mediated through specific alteration of 
histones.  Hypoxia enhanced CtBP repression of p16, while co-expression of wildtype 
E1A, but not the PLDLS deleted mutant, inhibited CtBP repression of the locus.  The 
other cyclin dependent kinase inhibitor at this locus, p15INK4b, is repressed by two 
CtBP dependent repressors Zeb1 (153) and ZNF217 (154). 
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It would seem then that ARF antagonizes a repressor of the other members of the 
INK4A/INK4B locus, opening up the possibility that ARF serves as a global defender of 
the tumor suppressor activities encoded in this region.  Future studies looking at ARF 
mutations should consider its indirect impact on both p16INK4a and p15INK4b, 
particularly in the setting of hypoxia or increased CtBP expression.  
 
CtBP as a therapeutic target 
 The current evidence supports the hypothesis that CtBP is likely an oncogene, 
modulating cellular functions that contribute to tumor initiation, survival, and 
progression.  It is also clear that multiple tumor suppressors keep these activities in 
check.  CtBP also contains an NAD/NADH binding site essential for its activity. 
This binding site is located in a conserved dehydrogenase domain, with enzymatic 
activity of unknown value to CtBP function. Based on its oncogenic properties and 
intrinsic enzymatic activity, CtBP represents a potential therapeutic target in neoplastic 
disease.   
 A search of the literature revealed that a novel CtBP substrate had been identified, 
4-methylthio-2-keto butyric acid (MTOB).  MTOB is the penultimate molecule in 
methionine salvage, and is converted to methionine by glutamine aminotransferase.  
CtBP reduction of MTOB to the hydroxy analogue 4-methythio-2-hydroxy butyrate 
(MTHB) shows bi-phasic kinetics, with increasing concentrations inhibiting enzyme 
activity (Figure 1.9) (155).  This compound had been previously identified as apotogenic 
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by an undetermined mechanism (156, 157).  Given the apoptotic activity of the molecule, 
as well as its ability to inhibit CtBP enzyme activity, I hypothesized that MTOB  
induced apoptosis was mediated through inhibition of CtBP.  In chapters two and three of 
this thesis MTOB is evaluated as a lead compound and proof of principle small molecule 
inhibitor of CtBP.
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Figure 1.9:  Substrate analysis for CtBP dehydrogenase activity.  CtBP enzyme activity on compounds 
related to the only previously known substrate, pyruvate, was determined by monitoring loss of NADH 
fluorescence. 4-methylthio-2-oxo butyrate (MTOB, structure shown) was the most efficient substrate, 
eighty times better then pyruvate, and nearly ten time better then the next best substrate 2-keto 
caporate (KC).  Other substrate including alpha-keto glutarate(αKG), glyoxylate,  and 2-keto isocaporate 
(KiC) are also analyzed.   
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Non-tumor suppressor functions of ARF 
 A series of recent reports have postulated that ARF plays a physiological role 
outside of tumor suppression (71-73, 158).  The evidence that ARF plays a role in 
functions as disparate as atherosclerosis, aging, and the innate anti-viral response, has 
been ascertained through use of knockout and transgenic mouse models and genome-
wide association studies.  ARF’s involvement in these processes, particularly evidence 
that it performs a role in innate viral defense will be considered (71-73, 158)within this 
dissertation.   
ARF and aging 
 ARF knock-out mice do not survive long enough to reveal an aging or metabolic 
phenotype.  However, animals containing extra gene doses of all three genes of the 
INK4/ARF locus, under control of their endogenous promoters and regulatory signals,  
were able to establish a role for the INK4/ARF locus in mediating the aging phenotype.  
Early assessment of these animals suggested that increases in median longevity were 
dependent on increased tumor suppression (159).  Further analysis, and comparison to 
animals containing an extra gene dose of p53, or p53 and INK4/ARF showed incredibly 
robust increases in tumor suppression.  Interestingly ARF/p53 mice also showed a 16% 
increase in median longevity, on par with that seen with calorie restriction protocols for 
extended mice longevity (158).  Studies in these mice showed an increase in expression 
of a stress response program controlled by p53.  Sestrins control anti-oxidant activity, and 
their up-regulation in these mice resulted in lower levels of oxidized lipids in proteins in 
aged mice.  This program appears to require ARF, as ARF null MEFs show no up  
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regulation of either Sestrin1 or 2 in response to stress.  In addition, mice with only an 
extra gene dosage of INK4/ARF showed a significant 20% increase in median cancer free 
survival, despite also carrying an extra gene dose of p16INK4a, which is generally seen 
as accelerating normal aging as a cost of tumor suppression, particularly when over-
expressed.   A robust expansion of these studies, including generation of animals 
containing two extra gene dosages of either INK4/ARF or p53 has confirmed earlier 
observations.  In a dose dependent fashion, additional ARF/INK4 gene doses increased 
both overall and tumor-free survival compared to wild type mice, while an extra dose of 
p53 did not (71).  Anti-oxidant pathways were again increased, with reduced reactive 
oxidative species in the tissue of aged animals.  An additional observation of sterility was 
seen in the males carrying two extra gene doses of INK4/ARF, resulting from a process 
similar to sertoli only cell syndrome where no Leydig cells are observed.  These results 
indicate a possible role for ARF in normal physiology or the organismal response to non-
oncogenic stress.   
 In a series of related studies using human populations, a role for the INK4/ARF 
locus in aging related diseases has been postulated.  Genome wide scans for SNP’s 
associated with type 2 diabetes and coronary artery disease have shown positive 
associations of these diseases with SNP’s located in the CDKN2A/CDKN2B locus, 
where ARF is located (160-163).  An additional study has shown that the link between a 
SNP in the gene linked with Cornary Artery Disease (CAD) is stronger in diabetic 
patients with poor glycemic control (164).  Analysis of peripheral blood T-cells from 180 
different patients indicates a strong correlation between atherosclerosis associated  
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INK4/ARF SNP’s and decreased expression levels of all members of the locus (165).  
These studies have not implicated which member of the locus is likely responsible, or if it 
is some combination there of.  A recent study has implicated a specific role for ARF in 
the phenotypes associated with these polymorphisms.  ARF-null mice were crossed with 
ApoE null mice and fed an atherogenic diet to determine the impact of ARF loss on 
atherosclerosis (72).  ARF loss exacerbated atherosclerotic plaque formation in the aortas 
of the double null animals relative to the ApoE null mice. Examination of these plaques, 
as well cultured macrophages and vascular smooth muscle, showed greatly decreased 
apoptosis in the ARF null lesions.  Thus, reduced ARF mediated apoptosis could be 
responsible for mediating the increased risk of arterial disease associated with particular 
SNPs.  These studies raise the importance of performing experiments under the 
appropriate stress conditions or within the appropriate disease model when attempting to 
assess ARF’s role in physiological and non-cancer related pathologies.   
ARF and Innate Immunity  
 Recently, a surprising connection was made between the ARF cellular tumor 
suppression network and viral immunity.  The ARF tumor suppressor protein is normally 
activated by the expression of activated oncogenes, as detailed above.   A cascade of anti-
tumor effects ensues, mediated in part by the activation of p53, followed by the growth 
arrest or apoptosis of individual cells. In mice infected with VSV and other interferon-
sensitive viruses, germline deletion of ARF led to heightened viral pathogenesis and 
decreased survival of infected animals (73), while an extra gene dose of INK4/ARF 
reduced viral replication and infectivity.  Examination of the ARF promoter revealed an  
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interferon sensitive response element (ISRE) that increased transcription upon viral 
infection and interferon stimulation.  The cell autonomous mechanism of ARF’s anti-
viral activity was traced to its ability to promote the release of Protein Kinase R (PKR) 
from an inactive nucleolar store into the cytoplasm, allowing PKR to phosphorylate 
eIF2α and IκB, and inhibit protein translation.  
 ARF has also been found to interact with several human pathogens.  The Human 
Papilloma Virus (HPV), encodes two oncogenic proteins, E6 and E7, capable of 
inhibiting the tumor suppressors p53 and Rb respectively (166).  Over-expression of ARF 
inhibits E7-mediated mediated degradation of Rb, a function that requires the N-terminal 
domain of ARF (167) .  Further studies have revealed E7 induces the up regulation of 
NPM, and that this up regulation is necessary for increased proliferation and inhibition of 
differentiation of infected primary cells (168).  This up regulation results in the 
sequestering of ARF in the nucleolus, and the knockdown of NPM results in the 
redistribution of ARF to the nucleus and cytoplasm.  The end result is p53 activation.  
ARF is also induced by Epstein Barr Virus (EBV) infection in resting B-cells, as well as 
in EBV transformed lymphoblastoid cell lines (LCL’s).  EBV encoded EBNA-5 interacts 
with p14ARF (169).  This interaction allows for increased survival of p14ARF 
expressing cells infected with EBV.  EBNA-5 and ARF appear to co-localize in non-
nucleolar inclusion bodies, along with p53 and MDM2, as well as components of the 
proteasome. The authors conclude that the lack of increase in p14ARF protein levels, 
despite increased mRNA, imply that ARF-p53 complexes are being targeted for 
degradation in these bodies.   ARF and p53 have also been linked to apoptosis induced by  
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the ulcer causing, and gastric cancer associated bacteria H. pylori (170).  Gastric cells 
exposed to H. pylori had increased levels of ARF and p53, undergoing apoptosis.  Use of 
wild-type and ARF null MEFs revealed H. pylori induction of p53 and apoptosis requires 
ARF.  In light of the role ARF appears to play as an innate response to infection, it would 
be interesting to reevaluate previous assumptions that ARF and p53 responses to 
tumorgenic viruses are related exclusively to mitogenic stimuli.   
Tumor Suppressors and Viral Infection 
 Proteins such as Promyelocytic leukemia protein (PML), PKR, ARF, RNaseL, 
and p53 have all been demonstrated to respond to viral infection (171).  In particular p53 
has been shown to interact with viruses infecting both dividing (adenovirus, HPV) and 
non dividing (HIV, Herpes Simplex Virus1/2) cells (172) (173, 174).  The case of p53 in 
HIV infection is of particular note because of its connection to ARF, but also because 
there are conflicting reports as to whether p53 acts as a anti-  or pro-viral factor in HIV 
infection.   
 p53 is involved in both HIV-induced apoptosis and transcription from the viral 
Long Term Repeat (LTR) (175-177).  Mitochondrial pathway mediated apoptosis 
induced by the HIV envelope is dependent on p53 as its apoptotic mediator.  These 
proteins are up-regulated in the peripheral blood cells of infected patients, and cell culture 
experiments reveal activating phosphorylation events in response to HIV infection or 
treatment with soluble Env (175, 178-180).   
There have been conflicting reports regarding p53’s role in HIV transcription.  Wild type 
p53 can inhibit transcription from the viral LTR in both endogenous and over- 
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expressed settings (175, 176, 181).  This repression can be overcome by stimulation with 
tumor necrosis factor alpha, or Tat over-expression.  The alleviation of the repression 
with cytokine treatment was inferred as a possible mechanism for viral latency by p53 
transcriptional repression.  In another study over-expression of mutant p53 was found to 
promote viral transcription, and its silencing by RNAi was deleterious to HIV replication 
in two cell lines (182).  As these cells do not possess functional p53, inhibited by the 
presence of E6 in HeLa P4-R5 MAGI, and mutated in Sup-T1, it is not possible to make 
a final judgment on whether p53 activity in non-transformed cells in vivo will interact 
with HIV in a similar fashion.  However the ability of Tat and p53 to interact and 
modulate one another’s activity make the relationship between p53 and HIV infection in 
vivo a compelling one to study.   
 In addition, p53 interacts with the HIV proteins Nef and Vpr. Nef-bound p53 has  
decreased stability and protects cells from apoptosis, both alone and in the setting of HIV 
infection (183). Vpr and p53 are both involved in modulating transcription from the LTR 
by an unresolved mechanism (184, 185).  p53 also appears to contribute to Vpr mediated 
cell cycle arrest through up-regulation of p21WAF1.  To further complicate the role of 
p53 in HIV infection, a series of reports has linked cytoplasmic p53 to an increased 
fidelity of replication for reverse transcriptase through a 3’ exonuclease proof reading 
activity (186-192).  This exonuclease activity appears to be capable of removing 
nucleoside analogs, providing a potential drug resistance mechanism.  Taken together, 
along with the role of p53 in limiting viral infection of other pathogens, it would seem 
that HIV artfully balances the useful and deleterious effects p53 can have on replication. 
  
 
40 
 Current studies have not fully elucidated the mechanisms by which HIV 
modulates cellular functions, dependent or independent of p53.  Given the new evidence 
of ARF’s antiviral activity, as well as growing evidence of its ability to modulate cellular 
activities with and with out p53, ARF may play a role in HIV infection.  Several recent 
publications indicate ARF’s antiviral activity could be mediated through multiple 
mechanisms. The cyclin dependent kinase inhibitor, p21, is up-regulated downstream of 
p14ARF, and it was recently shown to be a HIV restriction factor in CD4 positive 
hematopoietic stem cells (193, 194).  Drugs that activate p21 expression were able to also 
block HIV replication.  p21 inhibition of HIV would be consistent with a p53 dependent, 
ARF mediated anti-viral response.   
 Another potential antiviral activity of ARF, specific to HIV, is its ability to target 
Tat for proteasomal degradation (195). ARF and Tat interact with the proteasome through 
the same ATPase component of the 19S regulatory subunit of the proteasome, Tat-
binding protein 1, TBP-1, or S6a (196, 197).  ARF over-expression is able to induce Tat 
degradation and block TAR mediated transcription of a luciferase reporter. It is unclear, 
however, if this activity is capable of inhibiting Tat mediated transcription in the setting 
of viral infection since these studies were performed by exogenous expression in the 
absence of HIV.  Additionally these studies were performed in cells of varying p53 status 
and function, further complicating interpretation of the results.  However, ARF mediated 
degradation of Tat would seem to be a potent mechanism for inhibition of HIV 
replication.   
 In a report that conflicts with the predicted role of ARF having antiviral activities,  
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the E3 ubiquitin ligase MDM2 was shown to bind, ubiquitinate, and induce the 
degradation of HIV Vif, reducing viral infectivity through increased APOBEC3G 
packaging in virions (198).  Since ARF is a well-characterized inhibitor of MDM2 
ubiquitin ligase activity, this report suggests ARF could be able to enhance HIV 
replication or infectivity.   
 ARF’s roles in modulating apoptosis, proliferation, ribosome biogenesis, and now 
the cell autonomous innate immune response could all be targets of HIV counter-
measures to the host anti-viral response.  ARF directly interacts with at least one HIV 
protein.  It also indirectly interacts with those viral proteins contacting the p53 pathway.  
Now MDM2 appears to be host interacting protein of HIV as well.  In Chapter Four of 
this thesis the interplay between ARF and HIV will be explored, in both transformed cell 
lines and in the natural host cell of HIV, CD4 positive T-cells. 
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Chapter-II 
The CtBP substrate MTOB is a safe and efficacious cytotoxic agent in vitro and in 
vivo. 
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Abstract 
 The CtBP transcriptional corepressors promote cancer cell survival and 
migration/invasion. CtBP senses cellular metabolism via a regulatory dehydrogenase 
domain, and is antagonized by p14/p19ARF tumor suppressors.  The CtBP 
dehydrogenase substrate 4-methylthio-2-oxobutyric acid (MTOB) can act as a CtBP 
inhibitor at high concentrations, and is cytotoxic to cancer cells.  MTOB induced 
apoptosis was independent of p53, and occurred in multiple cancer cell lines from 
different tissues of origin.  Combination of MTOB with known cytotoxic compounds can 
increase cell death synergistically.  MTOB did not induce cell death in mouse embryonic 
fibroblasts (MEFs), but was increasingly cytotoxic to immortalized and transformed 
MEFs, suggesting that CtBP inhibition may provide a suitable therapeutic index for 
cancer therapy. In human colon cancer cell peritoneal xenografts, MTOB treatment 
decreased tumor burden, with MTOB mice having smaller tumors and less acites 
production.  To verify the potential utility of CtBP as a therapeutic target in human 
cancer, the expression of CtBP and its negative regulator ARF was studied in a series of 
resected human colon adenocarcinomas. CtBP and ARF levels were inversely-correlated, 
with elevated CtBP levels (compared with adjacent normal tissue) observed in greater 
than 60% of specimens, with ARF absent in nearly all specimens exhibiting elevated 
CtBP levels.  Targeting CtBP may represent a useful therapeutic strategy in human 
malignancies.   
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Introduction 
 
The transcriptional co-repressors C-terminal binding protein (CtBP) 1 and 2 
repress gene expression by interacting with DNA binding transcription factors and 
recruiting to targeted promoters histone methyl-transferases, histone deacetylases, 
polycomb group proteins, and other chromatin remodeling proteins (98, 110, 199-202).  
CtBP targets include epithelial and proapoptotic genes, consistent with its known role in 
promoting cell survival and migration (142, 145).  Transcriptional repression requires 
CtBP’s dehydrogenase/NADH binding domain. Increases in intracelluar NADH levels 
promote CtBP oligomerization and transcriptional repressor activity (104-108, 203). 
Hypoxia and extraceullular glucose levels, both stimuli affecting NADH levels, modulate 
CtBP’s effects on cell survival and migration (145, 148). These findings have established 
CtBP as a redox sensor that regulates transcription based on the cell’s metabolic 
environment.   
 A growing body of evidence suggests CtBP plays a role in human cancer (141).  
CtBP promotes multiple pro-oncogenic activities, including EMT (142), cell 
migration/invasion (94, 95, 145), and cell survival (92, 142), through repression of 
epithelial genes such as keratin-8 and E-cadherin, and apoptosis genes such as Bik, Noxa, 
Puma, and PERP (142, 146). Additionally CtBP targets multiple tumor suppressors for 
down regulation, including PTEN, p16INK4a, and p15INK4b (94, 142, 152, 153).  
 In addition to opposing the activities of multiple tumor suppressors, CtBP is also 
the target of inhibition by multiple tumor suppressors.  In response to UV radiation, CtBP 
is phosophorylated by HIPK2 and targeted for ubiquitination and proteasomal mediated  
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degradation (113), resulting in apoptosis.  The adenomatous polyposis coli tumor 
suppressor (APC) targets CtBP for degradation, and may be a necessary step in adenoma 
formation (150, 151).  Finally, the tumor suppressor ARF can also down-regulate CtBP 
by targeting it for proteasomal degradation, inducing Bik dependent apoptosis (92, 93). 
Additionally, ARF is also capable of blocking CtBP mediated repression of PTEN, which 
inhibits CtBP-dependent, hypoxia-induced, cancer cell migration (94).   
While the physiologic substrate for CtBP’s dehydrogenase activity has not been 
definitively identified, the penultimate compound in the methionine salvage pathway, 2-
keto-4-methylthiobutyrate (referred to hereafter as: 4-methylthio-2-oxobutyric acid; 
MTOB), is a  specific and 80 to 5000 fold better substrate for CtBP than related 
compounds (155).  The enzymatic reaction shows bi-phasic kinetics, with higher 
concentrations of MTOB inhibiting the reaction. 
MTOB exhibits significant cytotoxicity against cancer cell lines, and is also an 
inhibitor of ornithine decarboxylase (ODC), which links methionine biosynthesis and the 
polyamine pathways (204).  ODC inhibition is not likely responsible for MTOB’s 
cytotoxicity in cancer cell lines, since supplementation with polyamines to bypass ODC 
inhibition was unable to reverse MTOB induced cell death (28).  MTOB is also a poor 
substrate for lactate dehydrogenase, suggesting it should not perturb the cellular 
NAD+/NADH ratio in the way that pyruvate can, leaving the true cellular mechanism for 
MTOB toxicity unknown (156).    
  Based on its oncogenic properties and intrinsic enzymatic activity, CtBP 
represents a potential therapeutic target in neoplastic disease.  The extent and mechanism 
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of the CtBP substrate MTOB’s cytoxicity was therefore studied in vitro and in vivo.  
Treatment with MTOB induced p53-independent apoptosis in human colon cancer cell 
lines at similar levels caused by depletion of CtBP by RNAi.  MTOB was also toxic in 
cancer cells originating from different breast malignancies, as well as those arising from 
bone and pancreas.   Long-term induction of cell death with MTOB could be achieved 
with much lower concentrations, and combination of MTOB with cis-platin resulted in 
synergistic loss of cell viability.  Furthermore, MTOB reduced migration in multiple cell 
types, similar to CtBP depletion or ARF over expression.  MTOB was demonstrated to be 
less toxic in primary and immortalized mouse embryonic fibroblsts (MEFs) than in those 
oncogenically transformed with MYC and RAS.  MTOB treatment also safely, and 
effectively, reduced the tumor burden in a peritoneal xenograft of human colon cancer 
cells in nude mice.  CtBP has been found to be up regulated in the adenomas of patients 
with Familial Adenomatous Polyposis  (FAP), but no systematic study has yet been done 
in sporadic colorectal adenocarcinoma. The expression of CtBP and its negative regulator 
ARF were examined in resected human colon adenocarcinomas, and CtBP and ARF 
levels demonstrated a strong inverse correlation, with CtBP1/2 up-regulated in greater 
than 60% of tumors compared with matched adjacent normal tissue.  CtBP may therefore 
represent a physiologically relevant therapeutic target.   
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Results 
The CtBP substrate MTOB induces cell death in human colorectal cancer cell lines.   
  
 CtBP transcription repressors represent potentially attractive cancer drug targets 
since they encode a potentially “druggable” dehydrogenase domain, and their silencing 
by RNAi leads to anti-cancer effects including apoptosis and abrogation of cancer cell 
migration/invasion (92, 94, 95, 107).  Based on the identification of MTOB as a CtBP 
substrate, as well as its reported cytotoxicity, the effect of MTOB on cell viability was 
determined in cell lines known to rely on CtBP for regulation of survival (HCT116 colon 
carcinoma wild type (+/+) or null (-/-) for p53 (Figure 2.1) (92, 156)).   After a 48 (left) 
or 72 hours (right) of treatment  a dose dependent loss in cell viability was observed, with 
a near complete lethal effect at 10mM after 72 hours.  The additional 24 hours of 
treatment, 72 versus 48 hours, shifted the IC50 nearly 5 fold, from 10mM to 
approximately 2-3mM.  There was no statistically significant difference in the effect of 
MTOB between the HCT116 +/+ and HCT116-/- cell lines, indicating that the loss of 
viability in these cells was p53 independent.  
MTOB induces cell death in human breast cancer cell lines 
 MTOB was previously reported to be toxic to the breast cancer cell line MCF-7.  
These findings were reproduced, with cells treated for 48 hours with MTOB and cell 
viability determined (Figure 2.2 A).  An approximate IC50 of 10mM was determined.  
Another breast carcinoma cell line, MDA-MB-231, which was previously characterized 
as a more aggressive cell line, was also tested for sensitivity to treatment with MTOB  
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(Figure 2.2 B).  MDA-MB-231 cells were equally sensitive to MTOB, with an IC50 
between 4 and 10mM. 
 MTOB’s specificity for targeting transformed cells was tested, by comparing its 
cytotoxicity in MCF7 breast carcinoma cells vs. the breast adenoma (immortalized) cell 
line MCF10A (205).   MCF7 or MCF10A cells were treated for 24 hrs with 10mM 
MTOB or vehicle, and either analyzed immediately, or observed for their ability to 
recover from the treatment 48 hrs later (Fig. 2.2 C).   MCF10A cells were resistant to  
MTOB induced cell death at 48 hrs compared to MCF7 cells, with cell viabilities of 
103% and 83%, respectively (p=0.001; Fig 2.2 C).  Moreover, as opposed to MCF10A 
cells, MCF7 cells increasingly lost viability 48 hrs after MTOB was removed, with the 
two lines exhibiting 93% viability, and 61% viability, respectively (p=0.005; Fig. 2.2 C). 
MTOB’s effect on cells did not require constant treatment, with cell death continuing 
after its removal.  In order to determine if this trend would hold with a longer initial 
treatment MCF7 or MCF10A cells were treated for 48 hrs with 10mM MTOB or vehicle, 
and analyzed as above (Fig. 2.2 D).  MCF10A cells were 77% viable after 48 hrs, but 
MCF7 cells were only 30% viable at that time point (p=0.00001; Fig. 2.2 D). MCF10A 
cells showed increased toxicity, with only 50% viability 48 hours later, however MCF7 
cells were completely wiped out with only1.5% cells still viable 48 hours after MTOB 
was removed (p=0.000001 Fig. 2.2 D). Thus a transformed cell line was more vulnerable 
to MTOB toxicity than a non-transformed cell line from the same tissue of origin.  
MTOB induces cell death in human cancer cell lines from multiple tissues of origin 
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 Having established MTOB toxicity in carcinomas originating from the colonic 
and breast epithelium, several cancer cell lines from both epithelial and mecenchymal 
origin were tested for MTOB toxicity (Figure 2.3). Mia Paca (pancreatic 
adenocarcinoma), ClonA (colorectal adenocarcinoma), and U2OS (osteosarcoma) cell 
lines were treated with MTOB or vehicle for 48 hours and cell viability determined by 
MTT assay.  All lines showed similar sensitivity, with an approximate LD50 of 4mM.  
Thus MTOB is toxic, in the milimolar range, to cancer cells originating from a wide array 
of tissues. 
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Figure: 2.1 The CtBP substrate MTOB induces cell death in human colorectal cancer cell lines.   A. 
The colon adenocarcinoma cell lines HCT116 wild type (+/+) or p53 null (-/-),were treated for 48 hours 
with MTOB or normal media (Control).  Cell viability was determined by MTS assay and normalized to 
the untreated samples.  The average of three separate experiments is shown, and error bars equal the 
standard error of the mean (SEM).  B. The colon adenocarcinoma cell lines HCT116 wild type (+/+) or 
p53 null (-/-),were treated for 72 hours with MTOB or normal media (Control).  Cell viability was 
determined by MTT assay and normalized to the untreated samples.  The average of three separate 
experiments is shown, and error bars equal the standard error of the mean (SEM).  
 
  
 
  
 
 
           
 
 
 
 
  
Figure 2.2: MTOB induces cell death in human breast cancer cell lines. A.  The breast carcinoma cell 
line MCF7 was treated for 48 hours with MTOB or normal media (Control).  Cell viability was determined 
by MTS assay and normalized to the untreated samples.  The average of three separate experiments is shown, 
and error bars equal the standard error of the mean (SEM).  B. The breast carcinoma cell line MDA-MB-231 
was treated for 48 hours with MTOB or normal media (Control).  Cell viability was determined by MTT 
assay and normalized to the untreated samples.  The average of three separate experiments is shown, and 
error bars equal the standard error of the mean (SEM).  C.  MCF-7 and MCF10A cells were treated with 
10mM NaCl or MTOB for 24 hrs, and then either assayed for viability by trypan blue, or washed and placed 
in normal media for 48 hrs. After 48 hrs of recovery, cell viability was again assayed by trypan blue.  The 
viabilities shown are normalized to the untreated time-matched controls.  Experiments were performed in 
triplicate and the p-values shown were determined by an unpaired t-test. D.   MCF-7 and MCF10A cells 
were treated with 10mM NaCl or MTOB for 48 hrs, and then either assayed for viability by trypan blue, or 
washed and placed in normal media for 48 hrs. After 48 hrs of recovery, cell viability was again assayed by 
trypan blue.  The viabilities shown are normalized to the untreated time-matched controls.  Experiments were 
performed in triplicate and the p-values shown were determined by an unpaired t-test. 
 
 
 
 
  
 
 
              Figure 2.3: MTOB induces cell death in human cancer cell lines from multiple tissues of origin.  
MiaPaca (pancreatic adenocarcinoma), U2OS (osteosarcoma), and ClonA (colon adenocarcinoma) 
cells were treated with the indicated concentrations of MTOB for 48 hours and cell viability 
determined by MTT colorimetric assay. Experiments were performed at least three times, and the error 
bars represent SEM. 
 
 
                      
 
  
 
 
         
Figure 2.4: MTOB can be effective in the micromolar range.  
A. (Top) HCT116-/- cells were plated at low density and treated with normal media or media 
containing the indicated amount of MTOB for 72 hours, and then replaced with compound free media 
for four days.  Colony formation was assessed by GIEMSA staining, and all wells were normalized to 
the untreated control. Experiments were done three times in duplicate, with a representative plate 
shown (bottom). Error bars represent the SEM.  B.  MDA-MB-232 cells were plated at low density and 
were treated with normal media (control) or media containing the indicated amount of MTOB for 3 
days, followed by four days in normal media. Cell survival  of colonies was determined by A595 of  
solubilized Giemsa-stained cells expressed relative to the untreated cells. Experiments were performed 
3 times in duplicate, and error bars represent the SEM.    C. The Non-Small Cell Lung carcinoma cells 
H1299 cells were plated at low density and were treated with normal media (control) or media 
containing the indicated amount of MTOB for 3 days, followed by four days in normal media. Cell 
survival of colonies was determined by A595 of  solubilized Giemsa-stained cells expressed relative to 
the untreated cells. Experiments were performed 3 times in duplicate, and error bars represent the SEM.     
                  
A 
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MTOB can be effective in the low millimolar to micromolar range  
 To determine if lower concentrations of MTOB might be effective over a longer 
term of treatment, a 7-day colony survival assay was performed using HCT116-/- cells.  
Cells were treated for 72 hours with indicated concentrations of MTOB, and then 
replaced with fresh compound free media for 96 hours before colonies were counted and 
normalized to untreated wells. (Figure 2.4 A top). All experiments were done in 
duplicate, and the average of three experiments is shown.  At seven days, the IC50 was 
approximately 200µM, and 1mM MTOB was 91% lethal; significantly more potent then 
at 72 hours, but closer to the expected IC50 for CtBP inhibition (Figure 1.9) (155).  
Similar results were obtained using HCT116+/+ cells (data not shown).  A representative 
set of giemsa stained colonies are shown (Figure 2.4A Bottom).    
 Similar experiments were performed using MDA-MB-231 cells, as well as a non 
small cell lung carcinoma cell line, H1299.  Both of these cell lines showed increased 
resistance to MTOB, with MDA-MB-231 cells having an LD50 of approximately 750µM 
and completely killed at 4mM MTOB (Figure 2.4 B), while H1299 cells had an LD50 of 
closer to 2mM, and were only completely killed with 10mM MTOB (Figure 2.4 C).  
Therefore MTOB efficacy varies by cell type, with more aggressive cell lines showing 
increased resistance, but with all cell lines maintaining sensitivity at a sufficiently high 
doses.   
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MTOB Can be combined with known chemotherapeutic compounds 
 In order to compare the efficacy of MTOB to other known cytotoxic agents 
HCT116-/- or HCT11+/+ cells were treated with doxorubicin (Dox), 5 fluro-uracil (5FU), 
or cis-platin in the presence or absence of 4mM MTOB for 48 hours. (Figure 2.5 A-C).   
Neither Dox nor 5FU showed any major interactions with MTOB, with resultant additive 
or even sub-additive effects in both HCT116-/- and +/+ cells.  However, when cells were 
treated with 1,10, or 25µM cis-platin in the presence or absence of 4mM MTOB a clear 
dose dependent loss of viability was seen in both cell lines, with the p53 null cells 
showing greater sensitivity to cis-platin at higher concentrations (Figure 2.5 C).  In the 
presence of 4mM MTOB and 1µM cis-platin cell viability dropped from 76% to 41% in 
the HCT116-/- cells, and from 79% to 52% in the HCT116 +/+ cells, suggesting an 
additive effect.  At higher cis-platin doses, the difference between control and MTOB 
treated cells disappeared in the p53-null cells, but was enhanced in the p53 wild type 
setting, with the cytotoxicity of 25µM cis-platin at 48 hours increasing from 46% viable 
to only 4% viable in the presence of MTOB.  
 These drugs were also combined with MTOB in the MCF7 and U2OS cell lines 
with similar results (Figure 2.5 D-F).  Dox and 5FU treatment in combination with 
MTOB showed little difference.  However, MTOB combined with cis-platin showed the 
opposite affect as seen in the HCT116 cells.  When 25µM cis-platin was combined with 
4mM MTOB, cells showed an increase in cell viability relative to cis-platin alone in both 
MCF7 and U20S cells, with a much more pronounced effect in MCF7s.  Thus, while  
  
 
 
  
           
Figure 2.5: MTOB Can be combined with known chemotherapeutic compounds.   A. HCT116-/- and +/+ 
cells were treated with the indicated concentrations of Doxirubicin in the presence or absence of 4mM MTOB 
for 48 hrs, and relative cell viability assessed by MTT assay.  Error bars represent SEM.  B. HCT116-/- and +/+ 
cells were treated with the indicated concentrations of 5-flurouracil in the presence or absence of 4mM MTOB 
for 48 hrs, and relative cell viability assessed by MTT assay.  Error bars represent SEM.  C. HCT116-/- and +/+ 
cells were treated with the indicated concentrations of cisplatin in the presence or absence of 4mM MTOB for 
48 hrs, and relative cell viability assessed by MTT assay.  Error bars represent SEM. D.  MCF-7 and U2OS cells 
were treated with the indicated concentrations of doxirubicin in the presence or absence of 4mM MTOB for 48 
hours, and relative cell viability assessed by MTT assay.  Error bars represent SEM. E.  MCF-7 and U2OS cells 
were treated with the indicated concentrations of 5-flurouracil in the presence or absence of 4mM MTOB for 48 
hours, and relative cell viability assessed by MTT assay.  Error bars represent SEM. F.  MCF-7 and U2OS cells 
were treated with the indicated concentrations of cis-platin in the presence or absence of 4mM MTOB for 48 
hours, and relative cell viability assessed by MTT assay.  Error bars represent SEM. 
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MTOB inhibits cancer cell migration 
 Inhibition of CtBP activity has been demonstrated to reduce cancer cell migration 
(94, 95, 145).  MTOB therefore should also negatively impact cancer cell migration.  In 
order to determine if MTOB inhibits migration a wound healing assay, previously 
employed to evaluate migration in the setting of ARF expression and CtBP silencing,  
was used  (Figure 2.6).  Several cancer cell lines were grown to near confluence, and a 
wound inflicted across the middle of the monolayer.  Pictures were taken immediately 
after, and the cells treated with fresh vehicle or 4mM MTOB containing media for eight 
or sixteen hours.  After the treatment was completed, pictures were taken of each well, 
and the average migration distance calculated, normalizing for initial would size.  After 
an eight hour treatment HCT116-/- and U2OS cells both showed significant decreases in 
migration distance when compared to the untreated with 51% or 58% of the controls’ 
migration respectively (Figure 2.6 A).  MCF7 cells showed no significant difference at 
eight hours.  After 16 hours of treatment, all cell lines tested, including the very motile 
MBA-MB-231 cells (Figure 2.6 B).  The MDA-MB-231 cells showed only 55% of the 
control migration, while the HCT116-/-, U2OS, and MCF7 showed 66%, 67%, and 67% 
of control migration respectively.  A set of images from the eight hour HCT116-/- 
migrations are included (Figure 2.6 C).  The decreased distance between the edges of the 
wound in the untreated sample compared to the MTOB treated sample at eight hours are 
clear, with the size of the initial wounds being almost identical.  MTOB, therefore, 
inhibits migration in multiple cancer cell lines, as would be predicted for a CtBP 
inhibitor.   
  
 
 
      Figure 2.6: MTOB inhibits cancer cell migration 
A.  MCF-7, U20S, and HCT116-/- cells were grown to near confluence, the cell monolayer wounded, 
and cell then cultured in 4mM MTOB or compound free (control) media for eight hours.  At eight 
hours wound healing was measured by comparing average wound closure between control and MTOB 
treated cells.  B.   MCF-7, U20S, MDA-MB-231, and HCT116-/- cells were grown to near confluence, 
the cell monolayer wounded, and cell then cultured in 4mM MTOB or compound free (control) media 
for sixteen hours.  At sixteen hours wound healing was measured by comparing average wound closure 
between control and MTOB treated cells.  C.  HCT116-/- cells photographed at the time of wound 
healing, or after eight hours of treatment with control or 4 mM MTOB.   
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MTOB sensitivity correlates with degree of transformation 
To investigate MTOB’s specificity for malignant cells, MTOB cytotoxicity was 
assessed in primary mouse embryonic fibroblasts (MEFs) with different genetic 
backgrounds.  Initially primary MEFs were treated with 10 or 4mM MTOB for 48 hours 
and viability assessed by trypan blue, with no differences seen between treated and 
control cells (Figure 2.7A). In a 7-day colony assay, primary MEFs likewise showed no 
difference in survival between MTOB-treated and untreated samples, confirming the lack 
of toxicity in the shorter experiment (Figure 2.7B). Immortalized MEFs from p19ARF 
null mice, however, showed greater sensitivity to MTOB, with a 65% reduction in 
survival.  Transformation of p19ARF -/- MEF’s with c-MYC and activated RAS 
rendered cells substantially more vulnerable to MTOB treatment, with 4mM MTOB 
reducing survival by 98%.  Thus, increasing cellular transformation renders cells 
sensitive to CtBP inhibition by MTOB.   
 
MTOB is well-tolerated and effective In Vivo 
Prior to xenograft studies, MTOB toxicity was assessed in nude mice.  Three mice 
received 750mg/kg MTOB by peritoneal injection twice a week for four weeks, and were 
then sacrificed.  The mice showed no signs of illness or distress at the time of sacrifice.  
Tissues from the major organs from one of each group were read in a blinded fashion by 
an outside pathologist and all major organs from the MTOB treated mouse looked no 
different histologically when compared to the PBS treated mouse.  This data, combined 
with previous studies of MTOB toxicity in animal and human nutrition (206)  
  
 
 
        
Figure 2.7: MTOB sensitivity correlates with degree of malignant transformation  
A. Primary (passage 2) wildtype mouse embryonic fibroblasts (MEFs) were treated with 0, 4 or 10 mM 
MTOB for 48 hours. Cell viabilities of the MTOB treated samples were determined by cell counting and 
trypan blue assay and normalized to the untreated samples.  The average of three separate experiments is 
shown, and the error bars represent SEM. 
B. Primary wildtype mouse embryonic fibroblasts (MEFs), immortalized ARF-/-  MEFs, and ARF-/- MEFs 
stably transfected with mutant Ras and c-Myc vectors were treated for 3 days with 4 mM MTOB or normal 
media (control), followed by four days in normal media. Cell survival  of MEF colonies was determined by 
A595 of  solubilized Giemsa-stained cells expressed relative to the untreated cells. Experiments were 
performed 3 times in duplicate, and error bars represent the SEM. 
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supported the conclusion that MTOB has limited toxicity in vitro and in vivo.  In order to 
determine MTOB’s efficacy in vivo a periotenal xenograft model employing HCT116-/- 
cells was used.   Nude mice were injected with 3x106  HCT116-/- cells into the 
peritoneum.  Seven days later mice were randomized into control or treatment groups and 
intra-peritoneal injections with PBS or 750mg/kg MTOB were begun three times a week.  
Mice were assessed for tumor free survival, tumor weight, and production of ascites 
(Figure 2.8). 
Mice treated with MTOB showed a median tumor free survival of 38 days 
compared to 35 days for PBS treated mice, with a Log Rank test p-value of .08 (Figure 
2.8A).   However, 48% of MTOB treated mice were still tumor free after all PBS treated 
mice had visible tumor, and 16% of the MTOB mice had no tumor at the end of the 
study, suggesting MTOB was effective in treating at least some of the tumors.   
After sacrificing the animals based on morbidity of tumor progression or by virtue of 
achieveing the study endpoint of 8 weeks, tumor burden was determined by total tumor 
weight and total ascites (Figure 2.8B).  Tumor masses accumulated on the viscera and 
peritoneal surfaces with no apparent invasion of other organs. PBS treated animals had 
tumors weighing an average of 4.7 grams, while MTOB treated tumors were significantly 
smaller, weighing an average of 1.2 grams (t-test p-value =.0007) (Figure 2.8 B left) .  
Ascites were aspirated prior to necropsy, and typically large volumes of bloody fluid 
were removed.  Only one MTOB treated animal had an ascites at all, while all but two of 
the PBS treated mice exhibited ascites.  The average fluid removed from PBS mice was 
5.7mL, while an average of 1.25mL in the MTOB mice was attributed to        
  
 
 
           
 
 
 
 
 
 
Figure 2.8: MTOB is well-tolerated and effective In Vivo 
A. Tumor free survival (TFS) of Nu/Nu mice inoculated with HCT116-/- cells and treated one week later with PBS 
or 750 mg/kg MTOB three times a week for 7 weeks, unless mice were euthenized sooner due to progressive 
tumor growth.  p= 0.08 for comparison of median TFS between PBS and MTOB treatment.  B. Tumor burden was 
assessed by measuring total peritoneal tumor weight at time of death or sacrifice (left), and by measuring the 
volume of ascites before necropsy (right).  Treatment groups were compared by unpaired t-test with tumor weight 
and ascites both significantly less in the MTOB group (p= 0.007 and 0.04, respectively). Error bars indicate SEM.  
C. Sections of paraffin embedded HCT116-/- peritoneal xenograft tumor isolated at necropsy from PBS or MTOB 
treated mice were stained with hematoxylin and eosin.  Low power (100x) and high power (400x) fields from both 
PBS and MTOB treated animals are shown.  D. Tumor weights for MTOB and PBS-treated tumors were plotted 
against days of survival, analyzed by linear regression, and the slopes compared by ANCOVA, with a p-value of 
0.0009. 
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just a single mouse (t-test p-value =.04) (Figure 2.8B Right).  Both measures of disease 
burden showed significant reduction with MTOB treatment, suggesting MTOB is 
effectively reducing tumor burden in the HCT116-/- peritoneal xenograft model.   
Tumors were fixed in formalin and paraffin embedded tumor sections were 
stained with hematoxylin and eosin (Figure 2.8C).  Histological analysis revealed poorly 
differentiated adenocarcinoma, with normal tissue (stomach, intestine, peritoneum) 
sometimes captured on the periphery.  Many tumors had varying degrees of central 
necrosis and lymphocytic infiltrate.  Mitotic figures are readily identifiable under high 
power(40x) (Figure 2.8C). There was no gross histological difference between the tumors 
treated with PBS and those treated with MTOB.  
A drawback to the peritoneal model is that tumor mass cannot be accurately 
measured over time.  In order to look at the effect of MTOB on tumor size over time, 
animal survival and tumor weight were plotted for PBS and MTOB treated mice (Figure 
2.8D).  The two groups were fit by linear regression (PBS slope =.26, MTOB slope= -
.008) and the slopes variance from zero determined by an F-test of the model, with the 
PBS slope being significantly non-zero, p=.001, and MTOB slope not different from zero 
(p=.6).  The two lines were then compared to each other by  analysis of co-variance 
(ANCOVA), varying from one another significantly, with a p-value of .0009. Hence, 
PBS treated mice grew tumors linearly proportional to their survival, while MTOB 
treated mice showed no increase in tumor size over time.    Taken together with the 
reduced disease burden overall, MTOB is a potentially effective therapeutic molecule, 
and CtBP is an excellent target for further therapeutic development.   
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CtBP and ARF levels vary coordinately in human colon tumors 
CtBP repressors represent potentially attractive cancer drug targets, but are only 
useful as such if they are expressed in tumors.   Recent studies have found increased 
levels of CtBP1 protein in adenomas from FAP patients (150, 151).  CtBP is regulated at 
the post-translational level by several tumors suppressors (92, 113, 150), but there has 
been no systematic examination of CtBP1 and CtBP2 protein expression in human 
tumors.  Since the cellular CtBP antagonist and tumor suppressor ARF is silenced due to 
methylation in ~22-38% of colon cancers (207), a series of 69 resected colon cancer 
specimens were analyzed for tumor-specific CtBP expression levels to probe whether 
CtBP over-expression occurred, and especially in tumors lacking ARF. Tumor specimens 
and corresponding adjacent normal tissue were analyzed for CtBP1/2, hARF, and 
GAPDH protein levels by immunoblot (Figure 2.9A) and CtBP2 and GAPDH mRNA 
levels by RT-PCR (Figure 2.9B).  Three CtBP and ARF expression patterns were 
observed (Figure 2.9A; Class I-III; summarized in Figure 2.9C). The majority of tumors 
(44/69, 64%) expressed substantially higher levels of CtBP1/2 than adjacent normal 
tissue, and ARF was undetectable in 38/44 (86%; a faint background band is seen 
migrating just below the ARF position in many samples) of the class I samples in either 
normal or tumor tissue (Figure 2.9A, #1-3).  25 % of tumors demonstrated a striking 
absence of CtBP1/2, and most of these (14/17, 82%) exhibited expression of p14ARF 
(class II, Fig. 2.9A, #4-6).  Notably, the matched normal samples for Class II tumors 
invariably contained detectable and comparatively high levels of CtBP1/2 protein, as also 
seen in matched normal samples from Class III tissues (where CtBP levels were the same 
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in normal and tumor tissue), but unlike the matched normal class I specimens (Figure 
2.9A). ARF was detected in 3/8 class III samples, but at lower levels of expression 
compared to class II tumors, and variably in tumor or normal tissue (e.g. #8, Figure 
2.9A).  The inverse correlation between ARF and CtBP was statistically significant for 
comparison of ARF/CtBP expression pattern between samples in Class I vs. II  p=0.0001, 
but only trended to significance for comparisons of class I or class II samples vs. class III 
samples (Class II vs. III  p=0.06, and Class I vs. III  p=0.12) likely because of the small 
numbers of samples in classes II and III.  Examining the inverse correlation of ARF and 
CtBP expression across all tumor samples revealed a highly significant chi square value 
of 26.7 (2 degrees of freedom, p<0.00001).   
RT-PCR analysis of these tissue samples for CtBP2 mRNA showed no consistent 
or significant difference between normal and tumor specimens across all classes (Figure 
5B), suggesting that the loss of CtBP expression in Class II tumors and the increase in 
CtBP expression in Class I tumors, was post-transcriptional, possibly related to ARF-
mediated regulation in the majority of class II tumors, or other ARF-independent 
mechanism in the minority of class II tumors lacking ARF expression. Taken together, 
the analysis of a series of colorectal cancer resection specimens demonstrated an inverse 
relationship between ARF and CtBP protein expression in ~75% of tumors, which is 
consistent with previous results from cell line based studies (92).  Additionally a majority 
(66%) of colon tumors exhibited levels of CtBP expression greater than that seen in  
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normal tissue, suggesting that a CtBP inhibitor, such as MTOB, could be of utility in 
colon cancer therapy, and of most utility and specificity in class I colon tumors. 
  
 
 
           
Figure 2.9: CtBP and p14ARF levels in human colorectal adenocarcinomas are inversely-
correlated. A.  Samples from colorectal adenocarcinoma specimens were analyzed by immunoblot for 
levels of p14ARF, CtBP1/2, and GAPDH. Tumors were separated into three groups based on the CtBP 
levels in tumor vs. normal tissue.  Representative blots from the three groups are shown.   B.  RNA was 
isolated from the same tumors and RT-PCR performed to determine CtBP2 and GAPDH mRNA levels 
in tumor vs. normal tissue.  C.  Summary of the three classes of colorectal tumors based on CtBP and 
ARF expression levels. The inverse correlation of ARF and CtBP1/2 expression was significant by exact 
Fischer’s test with p=0.0001 for Class I vs. Class II, p=0.06 for Class II vs. Class III, but not siginificant 
for the comparison of Class I vs. Class III (p= 0.12). 
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Discussion 
 
 CtBP is one of only a very few transcription factors that harbor an intrinsic 
enzymatic, and thus druggable, functional domain.  CtBP is a potential therapeutic target 
in cancer, therefore, due to its numerous pro-oncogenic properties (92, 95, 141, 145).  
Here I have shown that the CtBP substrate MTOB mimics CtBP inhibition in vivo.  
MTOB is toxic to cancer cells originating from multiple tissues, and inhibits cancer cell 
migration. Immortalized and transformed MEFs were sensitized to MTOB cytotoxic 
effects in comparison to normal MEFs, indicating that MTOB may exhibit its toxic 
effects specifically in cancer cells.  In vivo testing of MTOB in colon cancer peritoneal 
xenografts demonstrated it to be a safe, well-tolerated therapy, with an ability to limit 
tumor growth, ascites production, and possibly prolong survival. 
In an effort to validate the usefulness of a CtBP inhibitor in human cancer, I have 
shown that CtBP1/2 protein is over-expressed relative to normal tissue in 64% of resected 
colorectal tumors, likely due to concomitant ARF loss and increased CtBP protein 
stability.  Only a minority of tumors (25%) exhibited low CtBP levels, and in this group 
of tumors, ARF and CtBP expression were inversely correlated in ~80% of specimens.  
Thus, abnormally high levels of CtBP were associated with greater than 50% of colon 
adenocarcinoma specimens, suggesting that a substantial fraction of colon cancers may 
exhibit heightened sensitivity to anti-CtBP therapy. 
 While MTOB had been identified as an in vitro substrate for the CtBP 
dehydrogenase, the mechanism by which MTOB functionally interacts with CtBP in the 
cellular context was not known.  Here I have shown that MTOB mimics inhibition of  
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CtBP activities in vivo, with MTOB reducing cancer cell survival and migration just as 
seen with CtBP depletion by RNA interference or ARF expression . CtBP inhibition by 
RNAi has been shown to be toxic to both colon and breast cancer cells previously (92, 
93, 208).  Cancer cell migration can also be inhibited by loss of CtBP activity, either by 
RNAi, specific down regulation by p14ARF, or even through treatment with pyruvate, 
which can both reduce whole cell NADH levels, but also impact CtBP as a very weak 
substrate (94, 95, 145).   
 The evidence to date suggests that MTOB or other compounds that target CtBP 
are viable candidates for therapeutic development.  MTOB is toxic to a variety of cancer 
cell lines derived from many different tissues (this work and (156)).  In our study, MTOB 
toxicity was relatively specific for transformed cells, with early passage mouse 
embryonic fibroblasts showing near complete resistance to the compound.  MTOB has 
been evaluated as a methionine supplement in livestock feed (206), as well as used in the 
treatment of uremic patients, without reported toxicity (209-211).  The oral doses used in 
both humans and animals were on the order of grams/day, with chicks showing no 
toxicity after receiving 15g/kg daily (206), suggesting the compound is well tolerated by 
healthy tissues in animals, as well as humans.   
 As to why MTOB is selectively more toxic to transformed cells is not yet clear.  
CtBP1/2 hetero- and homozygous knockout MEFs grow normally, but are hypersensitive 
to pro-apoptotic stress (97, 142).  Possibly the underlying constitutive apoptogenic 
stresses found in malignant cells (212) cause them to rely on enhanced or constitutive 
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CtBP activity, whereas non-transformed cells are not under constant stress, and thus 
should be less dependent on CtBP activity for survival.   It is therefore unclear whether  
improvement in MTOB’s inhibition of CtBP with a more potent chemical inhibitor would 
improve or reduce the therapeutic window of CtBP inhibition.  
 The evidence for a role of CtBP in human cancer is growing.  CtBP has been 
shown to regulate processes important for oncogenesis, tumor maintenance, and 
progression/metastasis (141).  I have demonstrated that the CtBP substrate and 
methionine salvage intermediate, MTOB, preferentially kills cancer cells.  MTOB can be 
successfully, and safely delivered to tumor cells in vivo.  These findings suggest that the 
dehydrogenase activity of CtBP proteins may represent a viable drug target. In the next 
chapter the mechanism of MTOB induced cell death will be explored, and the specificity 
of CtBP as a target determined.   
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Materials and Methods 
Chemicals. 4-methylthio-2-oxobutyric Acid (Sigma) was dissolved in cell specific 
media, 0.2um filtered, and diluted to final concentration before addition to cultured cells.   
Plasmids and viral expression vectors.  c-Myc and RasV12 expression plasmids were 
generously provided by Dr. Ron DePinho. 
Cell culture and transfection.  HCT116 human colon cancer cells (ARF silenced) with  
(-/-) and without (+/+) targeted deletion of p53 (213) were grown in McCoy’s 5A 
medium with 10% fetal bovine serum and 100 U/ml penicillin, 100 µg of streptomycin.  
MEFs were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented 
with 10% fetal bovine serum, 100 U/ml penicillin, 100 µg of streptomycin, and incubated 
in humidified 5% CO2 at 37°C.  MCF7 human breast carcinoma cells were grown in the 
same medium, with glucose levels reduced to 1 g/L.  MCF10A human breast adenoma 
cells were grown in DMEM F-12 media as described (205).  Mammalian expression 
plasmids were transfected using Fugene (Roche). The same conditions were used for 
MBA-MB-231 breast carcinoma cells, MiaPaca pancreatic cancer cells, and ClonA colon 
adenocarcinoma cells.  
Immunoblotting.  Cells were lysed in lysis buffer (20 mM HEPES pH 7.4, 0.5% Triton 
X-100, 2 mM MgCl2, 10µM ZnCl2, 2 mM NEM, 1 mM PMSF, 240mM NaCl) containing 
protease inhibitor tablets (145). Antibodies used were as follows: CTBP1, CtBP2 (BD 
Biosciences), hARF (Novus), V-5 (Invitrogen), GAPDH (Advanced Immuno), Anti-
rabbit IgG-horseradish peroxidase and anti-mouse IgG-horseradish peroxidase conjugates  
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(Jackson Immunoresearch) were used with ECL detection (GE Healthcare) for detection 
of immunoblots.  
Cell viability, colony and relative survival assays.  For viability analysis, cells were 
analyzed by trypan blue staining or MTT viability assay.  For trypan blue studies, cells 
were trypsinized, washed, and mixed 1:1 with trypan blue solution and counted with a 
hemocytometer.  For MTT assays, cells were combined with MTT reagent (Calbiochem) 
according to manufacturers instructions, and developed for one hour before determination 
of A595.    
Colony assays were performed in duplicate in six well plates.  Cells were plated at 
a limiting dilution and treated for 72 hours with no additive or MTOB-containing media.  
After 72 hours, media was replaced with fresh media without MTOB every two days, 
until fixation with methanol and acetic acid.  After fixation, colonies were stained with 
Giemsa, and then either counted, or resolubilized in methanol and SDS followed by 
determination of A595 as described (214). 
Tumor Sample Analysis.   Whole cell lysates (for protein analysis) and total RNA from 
tumor and associated normal samples (colon adenocarcinoma resection specimens, 
UMass Memorial Cancer Center Tumor Bank, deidentified samples with stages I-IV 
represented) were prepared using a PARIS® kit (Ambion Inc, TX).  RT-PCR was 
performed using the Stratascript ® RT kit. The primers used for RT-PCR were CTBP2- 
sense (132-155) 5’CGAGACGAGAGTTTC ATCAC CTTA-3’ antisense (411-387) 5’-
GCGGATACCTTCACAAATTCTGTC-3’ and GAPDH sense (219-240)  
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5’-ATCACCATCTTCCAGGAGCGA-3’antisense (690-670) 5’-GCCAG TGAG 
CTTCCCGTTCA-3’.  
MTOB treatment of peritoneal xenograft tumors.  Mouse xenograft studies were 
approved by the UMass Medical School Institutional Animal Care and Use Committee.  
Male NU/NU mice (Charles River Laboratories) were inoculated with 3x106 HCT116-/- 
cells in PBS by intra-peritoneal injection. One week after inoculation, mice were 
randomized into groups (n =10 mice/treatment group) and injected three times a week 
(M,W,F) with either PBS or 750 mg/kg MTOB prepared in PBS.  Mice were necropsised 
at time of death, or sacrificed when determined by a third party to be moribund or too 
burdened by ascites. Tumor free survival was plotted as a Kaplan-Meier curve using 
Prism Graphpad software (GraphPad Software). Any ascites was aspirated before 
necropsy and volume quantitated in ml. Total peritoneal tumor mass was measured by 
weight in grams.    Tumor weight and ascites in MTOB vs. PBS treated mice were 
analyzed by unpaired student t-test.   Tumor weight as a function of survival time was 
analyzed by an F-test of both linear regression models and an analysis of covariance 
(ANCOVA), to determine the difference between the PBS and MTOB treated groups. 
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Chapter-III 
MTOB inhibits CtBP repression of pro-apoptotic proteins and induces p53 
independent cell death 
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Abstract 
 The CtBP transcriptional co-repressors promote cancer cell survival and 
migration/invasion. CtBP activity is sensitive to the metabolic activity of the cell, and is 
antagonized by p14/p19ARF tumor suppressors.  The CtBP dehydrogenase substrate 4-
methylthio-2-oxobutyric acid (MTOB) can act as a CtBP inhibitor at high concentrations, 
and is cytotoxic to cancer cells.  MTOB induced apoptosis in human colorectal cancer 
and breast cancer cell lines, as well as colon cancer cell peritoneal xenografts.  CtBP 
binding to the promoter of both the pro-apoptotic BH3-only gene BIK and the established 
CtBP target E-cadherin was diminished with MTOB treatment, resulting in up-regulation 
of both genes. Over expression of CtBP, or RNAi silencing of Bik rescued MTOB 
induced apoptosis.  Thus, MTOB  is an inhibitor of CtBP activity in vivo, and a potential 
lead compound for the design of a first in class chemotherapeutic agent.   
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Introduction 
 CtBP’s are transcriptional corepressors, working through various DNA binding 
transcription factors(109, 121).  CtBP1/2 can homo or hetero dimerize in order to form an 
active repressor complex (109).  CtBP oligomerization is regulated through NADH 
binding by its 2-D hydroxyacid dehydrogenase domain, allowing CtBP to be sensitive to 
the metabolic state of the cell (104, 108).  As a result CtBP activity is increased under 
hypoxic conditions often found in the tumor microenvironment.   
 The evidence for CtBP’s role in oncogenesis and tumor progression has grown, 
with CtBP identified as an antagonist to multiple tumor suppressors, while itself being 
targeted for degradation by several tumor suppressors (141).  Specific targeting of CtBP 
for degradation by the tumor suppressor 14ARF results in p53 independent apoptosis (92, 
93).  CtBP1/2-null MEFs are hypersensitive to apoptosis in response to death receptor 
ligand, DNA damage, and anoikis, (142). Microarray analysis has shown that epithelial 
specific and proapoptotic genes are up-regulated in these MEFs (142), and it is 
hypothesized that CtBP links the acquisition of apoptosis resistance to the Epithelial 
Mesenchymal Transition (EMT).  siRNA mediated CtBP knockdown in human tumor 
cell lines is sufficient to induce apoptosis on its own (92), indicating transformation is a 
sufficient source of stress to induce apoptosis with CtBP depletion.  
 The effects of CtBP on cell survival have been linked specifically to its repression 
of pro-apoptotic BH3-only genes, of which Noxa and Puma, as well as the related 
molecule PERP, were identified in a microarray comparison of wt and CtBP1/2 knockout 
MEFs (142).  The BH3only mechanism of action is to dissociate bax or bak from anti- 
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apoptotic bcl-2 family proteins, resulting in the eventual cytoplasmic release of 
cytochrome C (215, 216).  
 CtBP has been recently demonstrated to also repress the BH3-only gene Bik, 
through its interaction with the Basic Kruppel-like Factor (BKLF) (93).  Multiple BKLF 
binding sites were found in the promoter region of BIK, as well as other BH3 only 
proteins BMF, NOXA, PUMA, and Bim (142).  CtBP depletion by siRNA or ARF 
expression increased BIK expression and induced apoptosis in p53 deficient HCT116 
colon cancer cells.  Depletion of BKLF also reduced CtBP recruitment to the BIK 
promoter and up regulated BIK.   
While the physiologic substrate for CtBP’s dehydrogenase activity has not been 
definitively identified, the penultimate compound in the methionine salvage pathway, 
MTOB, is a specific and 80 to 5000-fold better substrate for CtBP then related 
compounds (155).  The enzymatic reaction shows bi-phasic kinetics, with higher 
concentrations of MTOB inhibiting the reaction.  Treatment of cancer cells with MTOB 
can induce cell death and inhibit cell migration in a manner similar to depletion of CtBP.  
The specificity of MTOB for CtBP has not yet been established in vivo.   
 In this study MTOB specificity for CtBP was tested. MTOB displaces CtBP from 
target promoters, including BIK, up-regulating CtBP repressed genes, with subsequent 
activation of apoptotic pathways. Tumors from nude mice injected with human colon 
cancer cells and treated with MTOB showed a marked increase in apoptosis.  MTOB 
dependent cell death was prevented when either CtBP was over expressed, or BIK was  
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down regulated using RNA interference, establishing the CtBP/BIK pathway as the target 
of MTOB cytoxicity in this system.   
 
Results 
MTOB modulates CtBP transcriptional functions and induces apoptosis  
 CtBP’s repression of apoptosis and other genes is dependent on active regulation 
by the dehydrogenase domain (104, 106, 108).  MTOB at high concentrations may inhibit 
the dehydrogenase activity and interfere with NADH binding, impacting repression 
function (155).  Reduction of CtBP2 levels by RNAi has been previously shown to 
decrease its recruitment to the BKLF binding site in the promoter of the BH3 gene Bik, 
causing apoptosis in HCT116-/- cells (93).  In order to determine if MTOB had a similar 
effect on promoter recruitment of the CtBP co-repressor complex, the Bik promoter was 
analyzed by CtBP chromatin immunoprecipitation (ChIP) in the presence and absence of 
MTOB.  HCT116-/- cells were treated with 4 mM MTOB or NaCl for 18 hours and the 
chromatin fraction harvested, immunoprecipitated with IgG, anti-CtBP1, or anti-CtBP2 
antibodies, and the ChIPs analyzed for bound Bik promoter (Figure 3.1A) (93).  Negative 
control PCR primers (NS) that amplify a fragment 10 kb upstream from the Bik promoter 
were used to establish specificity (Figure 3.1A).  PCR amplification of input chromatin 
with Bik and NS primers showed equal amounts of amplification in both treated and 
untreated cells, and there was little background binding of the Bik promoter in the IgG 
control ChIP (Figure 3.1A).  Bik promoter binding was nearly completely suppressed in  
  
 
 
         
 
 
Figure 3.1 MTOB modulates CtBP transcriptional functions and induces apoptosis. A.  MTOB 
displaces CtBP2 from the Bik promoter.  HCT116-/- cells were treated for 18 hours with 4 mM 
MTOB or NaCl (control), and CtBP2 and CtBP1 association with the Bik promoter assessed by ChIP 
using control IgG, anti-CtBP 1 or 2 antibodies and formaldehyde crosslinked chromatin.  DNA 
retained in the ChIPs was analyzed by PCR using either Bik promoter primers that amplify a 
fragment containing BKLF sites (Bik), or a fragment of DNA located 10kb upstream of the Bik 
transcription start site (NS).  B.  MTOB increases expression of Bik mRNA. Quantitative real-time 
PCR using RNA prepared from HCT116 p53-/-cells treated with NaCl (control) or 10 mM MTOB.  
Error bars are equal to the SEM. C. MTOB regulates Bik expression. HCT116 p53-/- cells were 
treated with control media (-), or media containing 1mM, or 4mM MTOB. Bik, cleaved caspase 3, 
and GAPDH levels were determined by immunoblotting of cell lysates prepared 24 hr after treatment. 
D. Sections of parrafin embedded tumor were analyzed for apoptosis by TUNEL staining.  5 high 
power fields were counted for 7 tumors each from PBS or MTOB treated animals, and the averages 
plotted (top).  Differences between the two groups were analyzed for statistical significance by 
Mann-Whitney test, with p= 0.0001.  A representative section of PBS and MTOB treated tumors are 
shown at 400x magnification.  
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the anti-CtBP2 chip from MTOB-treated cells, while the anti-CtBP2 ChIP from NaCl 
treated cells demonstrated easily detectable CtBP2 interaction with the Bik promoter 
(Figure 3.1A).  The anti-CtBP1 ChIP showed slightly different results, with less basal 
promoter binding in the NaCl treated sample, and a small fold change loss in Bik 
promoter binding, suggesting CtBP2 could play a larger role in regulating Bik expression, 
at least in HCT116-/- cells, with the caveat that the two antibodies may not provide equal 
signal.  
  Having demonstrated that MTOB displaces CtBP2 from the Bik promoter, 
MTOB’s functional effect on CtBP repressor activity was investigated. HCT116-/- cells 
were treated with 10mM MTOB or 10mM NaCl, and mRNA analyzed by qPCR for Bik 
expression (Figure 3.1B).   The MTOB-treated cells showed a six fold increase in relative 
Bik expression compared to vehicle treated cells (Figure 3.1B).   Bik protein levels were 
checked in HCT116-/- cells 24 hours after treatment with vehicle, 1mM, or 4mM MTOB 
(Figure 3.1C), and Bik levels increased in a dose dependent manner.  Treatment of 
HCT116-/- cells with MTOB also induced a dose dependent increase in caspase 
activation, as measure by levels of cleaved caspase 3 (Figure 3.1C).  Thus, MTOB 
decreased the occupancy of CtBP2 on a key target promoter, resulting in increased Bik 
gene expression, and activation of apoptotic pathways. 
 HCT116-/-  xenograft tumors described in the previous chapter were utilized to 
assess if MTOB induced apoptosis in vivo. TdT-mediated dUTP-biotin nick end labeling 
(TUNEL) staining was performed and quantified on seven PBS and seven MTOB treated 
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tumors with a significant 11-fold increase in %TUNEL positive cells in MTOB treated 
tumors (p=.002 by Mann Whitney/Wilcoxon rank sum test) (Figure 3.1D).  The range of  
apoptotic response to MTOB was variable, ranging from a 4 to 27 fold increase in % 
TUNEL positive cells (Figure 3.1D, top), and this might possibly explain the range of  
tumor weights observed in MTOB treated mice (Figure 2.8B).  Representative 
microgaphs at 400x magnification are shown of tumors from both PBS and MTOB 
treated mice, demonstrating a clearly higher level of TUNEL staining in the  MTOB 
treated tumor  (Figure 3.1D,bottom).   MTOB therefore induces apoptosis both in vitro 
and in vivo. 
 
MTOB up regulates other CtBP gene targets in breast cancer cells 
Bik expression and CtBP occupancy of the BIK promoter was unchanged in 
MCF7 cells after treatment with MTOB (data not shown).  To assess whether MTOB was 
affecting CtBP activity in these cells, the prototypical CtBP target, E-cadherin, was 
analyzed by CtBP chromatin immunoprecipitation (ChIP)  of its promoter in the presence 
and absence of MTOB.  MCF-7 cells were treated with 10mM MTOB or 10mM NaCl for 
20 hrs, and the chromatin fraction harvested, immunoprecipitated with IgG or anti-CtBP2 
antibodies, and ChIPs analyzed for bound E-cadherin promoter (145).  Negative control 
PCR primers (NS) that amplify a fragment 10 kb upstream from the E-cadherin promoter 
were used to establish specificity (Fig. 3.2A).  PCR amplification of input chromatin with 
E-cadherin and NS primers showed equal amounts of amplification in both treated and 
untreated cells, and there was little background binding of the E-cadherin promoter in the  
  
 
 
          
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2: MTOB modulates different CtBP targets in breast cancer cells 
A. MTOB displaces CtBP2 from the E-cadherin promoter.  MCF7 cells were treated for 20 hrs 
with 10mM MTOB or NaCl, and CtBP2 association with the E-cadherin promoter assessed by 
ChIP.  Specificity of the reaction was determined by comparison of CtBP binding to the E-
cadherin promoter fragment vs. a fragment of non-promoter DNA located 10kb upstream of E-
cadherin (NS), as well as an IgG control IP.  B. MCF-7 cells were treated with 10mM NaCl or 
10mM MTOB, and cell lysates immunoblotted for E-cadherin and GAPDH. C. MCF-7 cells were 
treated with MTOB or NaCl for 48 hrs.  Viability and apoptotic fraction were determined by PI 
staining and fluorescent caspase 3/7 substrate cleavage.  Representative FACS plots are shown, 
and the experiment was repeated three times. Top panel from left to right: 5, 10, 20 mM NaCl.  
Bottom panel from left to right 5, 10, 20 mM MTOB. Bold numbers in each quadrant represent % 
of cells in that quadrant.  The upper right and lower right quadrants represent non-viable and 
viable apoptotic fractions, respectively.  The upper left quadrant represents necrotic or late 
apoptotic cells, and the lower left quadrant represents viable, non-apoptotic cells.   D.    MCF-7 
cells were treated with 10mM NaCl or MTOB for 12,24, or 48 hours, and cell lysates analyzed by 
immunoblotting for NOXA and GAPDH. 
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IgG control ChIP (Fig. 3.2A).  E-cadherin promoter binding was nearly 
completely suppressed in the anti-CtBP2 ChIP from MTOB treated cells, while the anti-
CtBP2 ChIP from NaCl treated cells demonstrated easily detectable CtBP2 interaction 
with the         E-cadherin promoter (Fig. 3.2A).  In concordance with this result, E-
cadherin protein levels were markedly increased after treatment with 10mM MTOB 
(Figure 3.2B).  Thus, MTOB decreased the occupancy of CtBP2 on a key target 
promoter, and induced the expression of gene products normally repressed by CtBP.   
Without BIK up regulation, it was important to establish that MTOB was in fact 
inducing apoptosis in these cells.  MCF7 cells were then analyzed for caspase 3/7 activity 
to determine if the loss of viability after MTOB treatment was due to apoptosis (Fig. 
3.2C).  Cells were treated with 5, 10, or 20 mM NaCl or MTOB for 48 hrs, and then 
stained with PI and incubated with fluorescent caspase 3/7 substrate.  Control treated 
cells exhibited no significant loss of viability or increase in caspase activity (Figure 3.2 
C).  MTOB treatment induced a dose-dependent loss of viability and increase in the 
apoptotic fraction, as indicated by increasing caspase activity and PI uptake, with 20mM 
MTOB (Fig. 3.2C, bottom right) inducing the greatest amount of cell death (56% 
apoptosis).  A small fraction of cells treated with 20 mM MTOB (16%) lost viability but 
caspase could not be detected  (Figure 3.2C),  these cells may have been late apoptotic 
cells where caspase had leached out, or could have died by an alternative caspase-
independent necrotic pathway. 
 With MTOB induced apoptosis confirmed, alternative pro-apoptotic targets of 
CtBP were assessed.  Another BH3-only gene, NOXA, was found to increase in MCF7 
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cells treated with 10mM MTOB at 12, 24, and 48 hours after treatment (Figure 3.2D).  
Noxa levels increased over time, and similar to the effect on BIK in HCT116-/- cells.  
Attempts to stably silence NOXA expression with an shRNA, in order to evaluate its 
affect on CtBP toxicity, were not successful (data not shown).  It is therefore  
undetermined if NOXA, instead of BIK, is responsible for MTOB induced apoptosis in 
MCF7 cells.   
MTOB specifically targets the CtBP/Bik pathway.   
Having shown that MTOB treatment inhibits CtBP transcriptional repression of a 
target gene product, the hypothesis that CtBP is a primary target for MTOB was tested by 
rescuing MTOB cytotoxicity with CtBP over-expression.  HCT116-/- cells were stably 
transfected with human V5-tagged CtBP2 cDNA (CtBP2-V5) or empty vector (pCDNA), 
treated with 4mM MTOB or vehicle for 72 hours, followed by trypan blue staining for 
viability assessment (Figure 3.3). Total cell viability was reduced by 66% in the control 
cells treated with 4mM MTOB, while the CtBP2-V5 cells treated with 4mM MTOB 
showed no significant loss in cell viability (Figure 3.3A, left panel).  These results were 
mirrored by the increase in the percent dead cells in control cells from 12% to 46% in the 
vehicle and 4mM MTOB treated cells, respectively (Figure 3.3A, right panel).  The 
CtBP2-V5 cells showed no difference between the untreated and treated cells, with 13% 
and 12% dead cells noted, respectively (Figure 3.3A, right panel).  CtBP2-V5 cells were 
thus completely resistant to MTOB induced cell death.  This resistance correlated well 
with Bik levels in the two cell lines.  In the control cells treated with 4mM MTOB, there 
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was an induction of Bik levels compared to the untreated cells, whereas the CtBP2-V5 
cells showed no Bik induction upon MTOB treatment (Figure 3.3B).  Thus, rescue of  
MTOB-induced cell death by CtBP2 overexpression correlates strongly with suppression 
of Bik induction.  
To confirm that MTOB induced cell death was due to CtBP inhibition and de-
repression of Bik, HCT116-/- cells stably expressing GFP shRNA, or one of two different 
Bik shRNA’s (93), were treated with vehicle or 4 mM MTOB for 72 hours, and viability 
determined by trypan blue staining (Figure 3.4).  shGFP cells showed normal sensitivity 
to MTOB, with reduction in viability from 100% to 44%, and an increase in dead cells 
from 7% to 39% (Figure 3.4A, left and right panels) . Both shBik1 and shBik2 showed a 
significant ability to rescue MTOB-induced cell death, with shBik1 increasing viability 
post-MTOB from 44% in shGFP cells to 73% and 94% in shBik1 and shBik2 cells, 
respectively (Figure 3.4A, left panel).  When compared to MTOB-treated shGFP cells 
using a paired student’s t-test, both shBik1 and shBik2’s rescue of viability were 
significant, with p-values less than .002 in both cases.   Cell death was also significantly 
reduced in shBik1 and 2 cells post-MTOB, with reductions in cell non-viability from 
38% (shGFP cells) to 12% and 15% non-viability in shBik 1 and 2 cells, respectively 
(Figure 3.4A, right panel) .   The rescue of cell death was also very significant, with p-
values less then .0001 for both shBik1 and shBik2 compared to MTOB-treated shGFP 
cells.  Knockdown efficiencies for the two hairpins were unequal (Figure 3.4B) with 
shBik1 having reduced knockdown (30%) compared to shBik2 (>90%), correlating with  
 
 
  
 
 
            
   
 
Figure 3.3:  MTOB induced cell death is dependent on inhibition of CtBP mediated repression of 
Bik.  A. HCT116-/-  cells were transfected with CtBP2-V5 or empty pCDNA3 vector, and transfected 
cells were enriched by G418 selection for one week to form pooled cell lines. Once selected, cells were 
plated and treated for 72 hours with either 4mM MTOB or normal media (control).  Cell viability was 
then determined by trypan blue assay.  Experiments were performed in triplicate and error bars indicate 
the SEM.  B. Cell lysates were immunoblotted to detect expression of CtBP2, CtBP2-V5, and Bik in 
the presence (+) and absence (-) of 4mM MTOB. 
 
 
 
 
 
 
 
  
 
 
            
  
Figure 3.4: MTOB induced cell death is dependent on inhibition of CtBP mediated repression of Bik. A. 
HCT116-/- cells stably expressing one of two shRNAs targeting Bik or GFP under the control of the Tet-
repressor were plated in the presence of doxycycline for 24 hours before being treated with normal media or 4 
mM MTOB.  After 72 hours, cells were harvested and cell viability determined by trypan blue assay.  Error 
bars represent the SEM. Signifigance was determined by upaired student t-tests, with p-values shown. B. Cell 
lysates were immunoblotted to detect expression of Bik in the presence of shGFP or one of two hairpins 
targeting Bik, shBik1 and shBik2.  Bik levels were quantified by densitometry, and normalized for GAPDH. 
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the more robust rescue of viability seen with shBik2 (Figure 3.4A).  Thus, inhibition of 
CtBP2 repression of Bik is largely responsible for MTOB-induced cytotoxicity. 
 
Discussion 
 While MTOB has been identified as an in vitro substrate for the CtBP 
dehydrogenase,  the mechanism by which MTOB functionally interacts with CtBP in the 
cellular context was not known.  Here I have shown that MTOB regulates CtBP activities 
in vivo.  Repression of a specific CtBP gene product, BIK, was alleviated with MTOB 
treatment, coinciding with decreased CtBP occupancy on the target promoter and 
increased gene expression.  CtBP2 rescue of MTOB induced cell death was complete, as 
was RNAi knockdown of the BH3 only protein BIK, supporting the hypothesis that 
MTOB-induced cell death is caused by interfering with CtBP repression of BIK .  
 Bik has been implicated as a human tumor suppressor, with epigenetic silencing, 
deletions, or mutations detected in renal, colon, brain, and lymphatic malignancies (217-
220).  Bik upregulation is linked to apoptosis induced by a variety of anti-neoplastic 
agents such as cisplatin, adriamycin, 5’-aza-2’deoxycytidine (DNA methyltransferase 1 
inhibitor), and the proteasome inhibitor bortezomib (221).  Bik over-expression has been 
reported to reduce chemotherapy resistance in vitro (222), as well as dramatically reduce 
tumor formation in mouse models in vivo (223, 224).  Thus, molecules that can induce 
Bik expression, such as MTOB or another CtBP inhibitor, could be useful in the 
treatment of a wide spectrum of malignancies.   
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 In addition to up regulating pro-apoptotic gene targets, CtBP inhibition could 
have additional therapeutic value.  CtBP was recently identified as a transcriptional 
activator of the multi-drug resistance transporter (MDR1; Pg-p) (130).  In a 
chemoresistant cell line, sensitivity was reestablished with RNAi depletion of CtBP,  
corresponding with reduced CtBP binding of the MDR1 promoter. MTOB induction of 
chemotherapy sensitivity to other therapeutics, outside of its intrinsic induction apoptosis, 
may be clinically useful as well. 
 The evidence for a role of CtBP in human cancer is growing.  CtBP has been 
shown to regulate processes important for oncogenesis, tumor maintenance, and 
progression/metastasis (141).  I have demonstrated that the CtBP substrate and 
methionine salvage intermediate, MTOB, preferentially kills cancer cells.  I have 
identified CtBP, and its repression of Bik, as the putative target responsible for MTOB-
induced cell death.  MTOB can be successfully, and safely, delivered to tumor cells in 
vivo.  These findings suggest that the dehydrogenase activity of CtBP proteins may 
represent a viable drug target, and further detailed investigation of the mechanism of 
CtBP inhibition by MTOB and its clinical usefulness is warranted.   
 
Materials and Methods 
Plasmids.  V5-tagged CtBP2 expression plasmid pcDNA-V5-CtBP2 has been described 
(92).  Chemicals. 4-methylthio-2-oxobutyric Acid (Sigma) was dissolved in cell specific 
media, 0.2um filtered, and diluted to final concentration before addition to cultured cells.   
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Cell culture and transfection HCT116 human colon cancer cells (ARF silenced) with  (-
/-) and without (+/+) targeted deletion of p53 (213) were grown in McCoy’s 5A medium 
with 10% fetal bovine serum and 100 U/ml penicillin, 100 µg of streptomycin.  MCF7 
human breast carcinoma cells were obtained from ATCC and grown in the same medium, 
with glucose levels reduced to 1g/L. Mammalian expression plasmids were transfected  
using Fugene (Roche). HCT116-/- cells stably expressing shRNAs targeting Bik were 
described previously(93). 
Immunoblotting.  Cells were lysed in lysis buffer (20 mM HEPES pH 7.4, 0.5% Triton 
X-100, 2 mM MgCl2, 10µM ZnCl2, 2 mM NEM, 1 mM PMSF, 240mM NaCl) containing 
protease inhibitor tablets (145). Antibodies used were as follows: CTBP1, CtBP2 (BD 
Biosciences), hARF (Novus), V-5 (Invitrogen), GAPDH (Advanced Immuno), E-
cadherin, hBIK and Cleaved Caspase 3(Cell Signalling), Noxa, Anti-rabbit IgG-
horseradish peroxidase and anti-mouse IgG-horseradish peroxidase conjugates (Jackson 
Immunoresearch) were used with ECL detection (GE Healthcare) for detection of 
immunoblots.  
Apoptosis and Cell viability Assays.  For viability analysis, cells were either trypsinized, 
washed, and mixed 1:1 with trypan blue solution and counted with a hemocytometer.  All 
experiments were done at least three time, averages of all experiments and SEM are 
shown.  Unpaired t-tests were used to asses statistical significance. For apoptosis 
analysis, cells were trypsinized after 48 hrs of transfection, washed with PBS and 
incubated with Caspase 3/7 FITC substrate and propidium iodide according to the 
manufacturer’s instructions (Chemicon International), followed by FACS analysis. 
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Chromatin immunoprecipitation assay (ChIP) 
108 cells per ChIP assay were washed once in PBS and treated with 1% formaldehyde in 
cold PBS for 10 min at 4°C with continuous shaking. Glycine (final concentration 125  
mM) was added to quench the formaldehyde for 5 min at 4°C with continuous shaking.  
Cells were then harvested and washed twice with ice-cold PBS. Nuclei were isolated by  
incubating the cells in nucleus isolation buffer (5 mM PIPES pH 8.0, 85 mM KCl, and 
0.5% NP-40) for 20 to 30 min on ice. The nuclei were harvested at 4°C by centrifuging 
the cell suspension at 7000 x g for 5 min, and resuspended in 2 ml of RIPA buffer (150 
mM NaCl, 1% v/v NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris pH 8.0, 5 
mM ethylenediamine tetra-acetic acid (EDTA)) containing protease inhibitors. Chromatin 
was fragmented to approximately 200–700 bp by sonication. Nuclear debris was removed 
by centrifuging the lysates at 4°C for 15 min at 14,000 rpm. The lysate was precleared by 
incubation with the protein G Sepharose beads for 30 min at 4°C and 
immunoprecipitation was performed overnight at 4°C with the respective antibody. 
Protein G Sepharose beads were added and the immunocomplexes were allowed to bind 
to the beads for 2 hours at 4°C. The beads were then washed once each with RIPA buffer, 
RIPA buffer with 500 mM NaCl, immunoprecipitation wash buffer (10 mM Tris pH 8.0, 
250 mM LiCl, 0. 5% NP40, 0. 5% sodium deoxycholate, and 1 mM EDTA), and finally 
with TE (10 mM Tris pH 8.0, 1 mM EDTA).  Beads were resuspended in 200 µl of 
elution buffer (50 mM Tris, pH 8.0, 10 mM EDTA, 1% SDS) with Proteinase K (20 
mg/ml) and incubated overnight at 55oC. DNA was extracted using phenol–chloroform, 
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precipitated in the presence of glycogen by ethanol, allowed to air dry, and dissolved in 
TE. Immunoprecipitated DNA was diluted 10-fold prior to PCR. The following primers 
sets were used to amplify different regions of the genes indicated: Bik promoter primer  
set  (fragment endpoints -551 bp to -693 bp relative to Bik transcription start site) in 
which tandem BKLF-binding sites are present; sense  
5’TATACCAGGGCTGGAGTTAGGTCC3’ / antisense  
5’CTCACGTGCAGACCTGGTGAGA-3’; non-specific primers (NS) (fragment 
endpoints -9.5 to -9.3 kb relative to the Bik transcription start site) sense 
5’CCTAAGAAGCTGGCCACAGCTC-3’ / antisense 
5’CCATCATGTTGGCCAGAATGGTCTC-3’. 
E-Cadherin primers 5’ TAGCCTGGCGTGGTGGTGTGCACCTG3’ and 
5’GTGCGTGGCTGCAGCCAGGTGAGCC3’. 
TUNEL staining. After weighing, peritoneal xenograft tumors were fixed in formalin.  
Paraffin-embedded tumor sections were analyzed for apoptosis using a peroxidase based 
In Situ Cell Death Detection Kit (Roche). The staining was automated using the 
Discovery XT (Ventana Medical Systems). TUNEL positive cells from 5 fields from 
each slide, excluding necrotic fields, were counted. The Mann-Whitney/Wilcoxon rank-
sum test was used to determine statistical significance in fold change of % TUNEL 
positive cells using Prism Graphpad software.  Images were taken using an Olympus 
BX41 microscope (Olympus) with 20x or 40x lenses. The images were acquired with an 
Evolution MP 5.0 camera (Media Cybernetics) and Q Capture Pro 5.1, (QImaging) 
acquisition software. 
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Real-time quantitative PCR. mRNA transcripts for human Bik and GAPDH were 
analyzed by real-time quantitative reverse transcription-PCR (RQ-PCR) using SYBR  
green (Applied Biosystems) and an ABI 7300 (Applied Biosystems). Relative amounts of 
the mRNA transcripts were calculated using the ΔΔCT method with GAPDH mRNA as 
internal references. The primer sets used were Bik (sense: 5’TCCTATGGC  
TCTGCAATTGTCA-3’ / antisense: 5’-GGCAGGAGTGAATGGCTCTTC-3’), GAPDH 
(sense 5’-ATCACCATCTTCCAGGAGCGA-3’ / antisense 5’- GCCAGT  
GAGCTTCCCGTTCA-3’). 
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Chapter IV 
The Tumor Suppressor p14ARF Interacts with HIV-1 and Modulates Infection 
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Abstract 
 The p14ARF protein is a stress response protein that activates p53 and other stress 
pathways.  Recently, p14ARF was linked to the innate immune response to viral 
infection.  In this study the interdependency of ARF and HIV infection was investigated.  
ARF expression was determined for a variety of cell types upon HIV infection.  In every 
case, ARF levels exhibited dynamic changes upon HIV infection.  The impact of ARF 
over-expression or silencing by RNAi on HIV infection was also examined.  
Consistently, p24 levels were increased with ARF over-expression, and decreased when 
ARF was silenced.  Thus ARF and HIV modulate each other, and ARF may 
paradoxically play a positive role in the HIV life cycle.   
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Introduction 
 The role of the innate immune system and/or cell autonomous mechanisms in the 
host response to HIV-1 is not well understood.   Increased levels of interferon in long-
term non-progressors, as well as in asymptomatic individuals with low numbers of CD4 
T-cells, suggest a role for type-1 interferons in controlling HIV-1 infection (225-229).   
Induction of interferon production is capable of reducing HIV-1 production, but the 
mechanism has not been fully elucidated. At least one interferon-responsive gene, the 
double stranded RNA binding protein kinase, PKR, is capable of interfering with HIV-1 
replication (193, 230).   
Recently, a surprising connection was made between a cellular tumor suppression 
network and viral immunity. The expression of the p14ARF tumor suppressor protein is 
normally induced by the expression of activated oncogenes, such as c-Myc and mutant 
Ras (32, 231).  In mice infected with VSV and other interferon sensitive viruses, 
germline deletion of p14ARF led to heightened viral pathogenesis and decreased survival 
of infected animals (73, 231).  Examination of the p14ARF promoter revealed an 
interferon sensitive response element (ISRE) that increased p14ARF transcription upon 
viral infection and interferon stimulation (73, 231).  Increased expression of p14ARF 
upon viral infection led to increased cytoplasmic localization of the dsRNA sensitive 
kinase PKR, resulting in decreased global protein translation (73, 231).  These findings 
suggest a more general role for p14ARF in the interferon-dependent innate immune 
response.  
 Two recent publications suggest p14ARF may play a more specific, albeit  
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complicated role in the host cell response to HIV-1 infection.  Gargano et. al., showed 
that p14ARF promotes the proteasome-mediated degradation of HIV-1 Tat (195).  Izumi 
et. al. showed that MDM2, the target of p14ARF’s p53 dependent activities, binds, 
ubiquitinates,  and induces the degradation of HIV-1 Vif, reducing viral infectivity 
through increased APOBEC3G packaging in virions (198).  Since p14ARF is a well-
characterized inhibitor of MDM2 ubiquitin ligase activity (232, 233), it is unclear 
whether p14ARF will enhance or inhibit HIV-1 infection.   
 In this study I sought to identify interactions between p14ARF and HIV-1 by 
examination of the impact of HIV-1 on p14ARF expression and the effect of p14ARF 
modulation on HIV-1 replication. I found that HIV-1 infection modulated p14ARF levels 
in both transformed cell lines and primary T cells.  Furthermore, I observed that 
exogenous p14ARF expression enhanced HIV-1 production, while p14ARF silencing 
reduced HIV-1 replication. 
 
Results 
HIV infection modulates p14ARF expression in Transformed Cells  
 HEK 293T cells, a transformed cell line which expresses high endogenous levels 
of p14ARF, and has been used previously to study HIV-1 replication in vitro, was mock 
infected or infected with VSV-pseudotyped HIV-1 (Fig. 4.1A). p14ARF levels were 
reduced in HIV-1 infected HEK 293T cells compared to mock infected cells (Fig. 4.1A).  
Furthermore, a target of negative regulation by p14ARF, CtBP2, was up-regulated in 
response to HIV-1 infection. Thus, HIV-1 not only reduces ARF levels in infected cells, 
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        Figure 4.1: HIV infection modulates p14ARF expression in Transformed Cells. 
A. 293T cells were infected with VSV-G-pseudotyped HIV or with empty envelope.  
Cells were lysed after 48 hours and analyzed by SDS-PAGE. The lysates were 
immunblotted with the indicated antibodies.  B.  14ARF-positive H1299 and p14ARF-
silenced U20S cells were infected with pseudotyped HIV-1 for different durations of 
time.  Cells were lysed and separated by SDS-PAGE, and then immunoblotted for the 
indicated proteins. 
 
 
H1299 U2OS 
293T 
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but is also capable of interfering with p14ARF function in directing CtBP degradation.   
 To determine whether variations in the underlying epigenetic regulation of 
endogenous p14ARF expression could affect the dynamics of HIV-1’s modulation of 
p14ARF, two tumor cell lines, p14ARF-expressing H1299 lung carcinoma cells and 
p14ARF-silenced U20S osteosarcoma cells, were infected with pseudotyped HIV-1, and 
ARF levels were determined by immunoblotting (Fig. 4.1B).  The effect of HIV-1 
infection in these two tumor cell lines distinctly differed. In H1299 cells, the high basal 
levels of p14ARF were rapidly depleted by HIV-1 infection within four hours, followed 
by a modest recovery, but p14ARF levels never returned to baseline levels over the next 
two days post-infection (Fig. 4.1B). The rapid decrease in levels of the normally stable 
p14ARF protein after infection suggests that HIV-1 could negatively impact p14ARF 
protein expression/stability, with an in vivo half-life for ARF having been determined to 
be eight to ten hours, making the rapid loss of ARF seen at four hours to quick to be 
explained by a reduction in gene expression alone (233). In U20S cells, however, there 
was a surprising induction of p14ARF at 24 and 48 hours post-infection (Fig. 4.1B). This 
requires a strong stimulation of the p14ARF promoter to overcome epigenetic silencing 
of the ARF locus by hypermethylation in these cells. This suggests that HIV-1 induces 
either a direct or indirect transcriptional activation of the p14ARF locus in U2OS cells. 
p14ARF silencing by siRNA decreases HIV replication 
 Having established that HIV-1 impacts p14ARF expression in a variety of cell 
types, the ability of p14ARF to impact HIV-1 replication was investigated.  293T cells 
were transfected with mock, control or p14ARF siRNA 24 hours (Fig. 4.2A) before  
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Figure 4.2: p14ARF silencing by siRNA decreases HIV replication. 
A. Immunblot of lysates from 293T cells treated with mock, scrambled siRNA, or p14ARF siRNA for 48 hours.  
B.  293T cells were treated with mock, control or ARF siRNA as indicated for 24 hrs before infection with VSV-G 
pseudotyped HIV-1.  The supernatants were sampled every 24 hrs post infection and p24 levels determined by 
ELISA. The average of four separate experiments is shown, with the standard error of the mean (SEM), along with 
corresponding p-values for significant differences in p24 fold change between control and ARF siRNA treatments. 
There was no significant difference between mock and control siRNA.              
  
       A               
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infection with VSV pseudotyped HIV-1. The supernatants were sampled for p24 levels 
every 24 hours, and the values normalized to untreated controls (Fig. 2B).  Each 
experiment was performed four times, with the average fold change in p24 levels shown 
with the Standard Error of the Mean (SEM). While virus production showed little 
variability in the first 72 hours among the three groups, there was a significant reduction 
in p24 levels at four (34%) and five days (68%) post-infection in the p14ARF siRNA-
treated cells compared to the mock siRNA transfected cells. An unpaired t-test was 
performed for days four and five, with p= 0.01 and p= 0.05 respectively for the difference 
in p24 production between control and p14ARF siRNA treated. siRNA knockdown of 
p14ARF, therefore, decreased virus production in 293T cells. While raw numbers of p24 
production varied from experiment to experiment, signifigant differences were still seen 
when p24 (ng/mL) levels were just averaged across the four experiments without internal 
normalization, with control cells producing an average of1280 ng/mL p24 versus 690 
ng/mL in the ARF siRNA treated cells measured on the fourth day post infection.   
Modulation of ARF expression correlates with HIV replication 
 To confirm that experimental modulation of p14ARF levels could impact HIV-1 
replication, HeLa TZM-bl and 293T cell lines were transduced with p14ARF-expressing 
vs. control lentiviruses, and TZM-bl cell lines were also generated that harbored control 
or p14ARF shRNAs.  
  Stable control and p14ARF expressing 293T cell lines (Figure 4.3A) were 
infected with VSV-G pseudotyped HIV-1, and p24 levels determined over five or nine 
day time courses (Figure 4.3B). In two separate experiments, HIV-1 replication was 
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enhanced 150% to 600% in the presence of p14ARF over expression compared to 
control.  Absolute p24 levels for the first experiment (Figure 4.3B top) on day nine were 
1500 ng/ml in the control cells versus 2400 ng/ml in the ARF over expressing cells.  In 
the second experiment (Figure 4.3B bottom) p24 values on day five were 49000 ng/ml in 
the control cells versus 96000 ng/ml in the ARF expressing cells.  Differences between 
the two experiments are likely due to the use of different batches of virus for the two 
experiments, and relatively higher titers for the second experiment.  The rate of 
replication as well as relative differences between control and ARF expressing cells are 
consistent between the two experiments. These data were consistent with decreased HIV-
1 replication observed in the 293T cells treated with p14ARF siRNA, showing a direct 
correlation between ARF levels and HIV production (Fig. 4.2B). 
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        Figure 4.3: Modulation of ARF expression correlates with HIV replication. 
A. p14ARF immunoblots show overexpression in 293T cells infected with ARF cDNA 
containing lentivirus vs. empty virus B. In two separate experiments, control and ARF 
expressing cells were infected with VSV-G pseudotyped HIV and supernatants sampled 
on the indicated days post infection. Levels of p24 were measured by ELISA and fold 
change in p24 in the ARF cells relative to the controls cells is shown. C. p14ARF 
immunoblots of lysates from TZM-bl HeLa cells infected with ARF cDNA containing 
lentivirus vs. empty virus. These cells were then infected with the HIV-1NL4-3 infectious 
molecular clone, and p24 levels determined at the indicated days, expressed as relative 
p24 levels in the ARF expressing cells vs. the control cells.  D. p14ARF immunoblots 
show ARF silencing in TZM-bl HeLa cells infected with ARF shRNA vs. GFP shRNA. 
These cells were then infected with VSV-G pseudotyped HIV, and p24 levels 
determined at the indicated days, expressed as relative p24 levels in the ARF expressing 
cells vs. the control cells. 
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 In TZM-bl cells stably expressing p14ARF cDNA and infected with the HIV-
1NL4-3 infectious molecular clone, HIV-1 replication was enhanced 160%-1100% 
compared to TZM-bl cells transduced with control lentivirus (Fig. 4.3C).  In contrast, 
TZM-bl cells stably expressing p14ARF shRNA and infected with VSV-HIV showed 
HIV-1 p24 levels reduced to 56% of the control shRNA cells by day nine post-infection, 
with a steady decline in p24 levels relative to control shRNA cells over the entire time 
course (Fig. 4.3D). These results are all consistent with a positive impact of ARF 
expression on HIV replication.    
 To assess whether ARF and HIV levels were truly directly correlated, a further 
statistical analysis was performed.  The effect of stable ARF over expression in 293T 
cells was compared to the effect of ARF siRNA in 293T cells by a Mann 
Whitney/Wilcoxon rank-sum test.  This type of analysis treats each experiment as a 
different patient or sample, measured multiple times (days).  The fold change in p24 
levels from the four ARF siRNA experiments was compared to the fold change in p24 
levels from the two ARF over-expression experiments, and the difference in fold change 
in p24 between ARF over-expression and ARF silencing was significant, with  p= 0.002.   
The same analysis was performed consolidating all the data sets from both HeLa 
TZM-bl and 293T cells, and a p-value of 0.0006 was obtained for the difference in fold 
change of p24 between ARF over-expression and ARF silencing conditions.  These 
analyses suggest that manipulation of ARF levels will directly correlate with p24 levels 
regardless of cell type or time.  Comparison of the data sets at the time point with the 
most data points, five days after infection, also revealed a significant difference. The  
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ARF over expressing lines exhibited an average of 1.7±.1 fold change in p24 levels, 
while ARF depleted cell lines exhibited a 0.7±0.03 fold change in p24 across all cell 
lines.  An unpaired student t-test provided a p-value of 0.0009 for the difference in p24 
fold change at the 5 day time point.  The result remains significant if you only include 
data from 293T cells, with a p-value of 0.02.  Therefore, ARF and HIV levels are highly 
significantly correlated in multiple cell contexts.  Further data will be required to 
determine the effect of cell type and/or time on the nature of this correlation.   
HIV infection modulates ARF expression in primary cells.  
 In order to determine if HIV-1 also regulates p14ARF levels in primary cells, 
peripheral blood mononuclear cells (PBMCs) were mock-infected or infected with VSV 
pseudotyped HIV-1 NL4-3 for 24 hours, and all lysates immunoblotted for p14ARF and 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as a loading control. HIV-1 p24 
core protein levels were determined to confirm infection (data not shown).  Interferon 
alpha treatment was also performed to see if the reported ISRE site in the ARF promoter 
is responsive.  Cells infected with HIV-1 showed decreased levels of p14ARF at both 2 
and 24 hrs relative to levels in mock-infected cells (Fig. 4.4A).  Interferon alpha 
treatment did not increase p14ARF levels in these cells (Fig. 4.4A).  H1299 (ARF-
expressing) cell lysate was used as a positive control for ARF expression and migration 
in the ARF immunoblot (Fig. 4.4A).  HIV-1-1 thus caused a clear decrease in p14ARF 
levels early after infection. 
  To establish whether ARF levels are modulated after infection specifically in the 
natural host cell for HIV-1, CD4+ T-cells were infected with wild type HIV-1 and ARF 
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levels analyzed.  Cells were also treated with interferon alpha or mock infected, and 
lysates were collected at the same time points post-infection as above, with an additional 
time point at three days to determine how long HIV-1 infection’s impact on p14ARF  
levels lasts (Fig. 4.4B).  Lower levels of p14ARF were observed in HIV-1 infected cells 
compared with uninfected cells at 2, 24, and 72 hours post-infection.  Interferon treatment 
modestly increased p14ARF levels at 24 hours, suggesting the locus might be sensitive in 
these cells.  Similar results were observed in CD4+ T cells enriched from PBMCs 
obtained from a second donor (data not shown). 
 
  
 
09 
        Figure 4.4:  HIV infection modulates ARF expression in primary cells. 
A. PBMC lysates were harvested after being infected with HIV, treated with type 1 
interferon, or untreated.  Protein lysates were separated by SDS-PAGE and 
immunoblotted for the proteins indicated; The blot shown is representative of 
experiments repeated with two other donor PBMCs. B. CD4+ T-cells, enriched from 
PBMCs, were either infected with HIV, treated with type 1 interferon, or left untreated 
for 72 hours.  Lysates were harvested at indicated time points and immunoblotted for the 
indicated proteins. 
. 
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HIV infection suppress ARF mRNA levels in CD4+ T-cells  
 In order to determine if HIV modulation of ARF was occurring at the 
transcriptional level, CD4+ T-cells were mock infected or infected with wild type HIV-1, 
and cells were lysed at 4,24, or 48 hours after infection for ARF qPCR analysis.  ARF 
expression was significantly lower in HIV-1 infected cells at all time points (Figure 
4.5A).  The difference in ARF mRNA levels between uninfected and infected cells 
correlated well with protein expression at the early time point (Fig. 4.4B), but the large 
differences seen at 24 and 48 hours in mRNA do not seem consistent with observations 
of ARF protein expression in CD4+T-cells obtained from other donors (see Figs. 4.4B).  
Over the first 48 hours of infection, ARF mRNA levels were 12.3 times higher in 
uninfected cells (Figure 4.5B).  Thus HIV infection represses ARF mRNA levels 
consistently over time, while its impact on protein expression varies over time, 
suggesting that ARF is both transcriptionally and post-transcriptionally regulated in the 
setting of HIV infection.   Data from these studies cumulatively demonstrates that HIV-1 
infection is capable of modulating p14ARF expression in CD4+ T cells.
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Figure 4.5:  HIV infection suppresses ARF mRNA levels in CD4+ T-cells. 
A. Quantitative real-time PCR using RNA prepared from CD4+ T-cells enriched from 
donor PBMCs and mock or HIV-1 infected, was performed to measure changes in ARF 
mRNA.  Fold change, compared to infected cells, in ARF mRNA levels is shown at 4, 
24, and 48 hours after infection. B. Average fold change in ARF mRNA levels over the 
entire first 48 hours of infection.   
    
 
 
 
  
 
112 
Discussion 
Over expression of p14ARF by lentiviral transduction enhanced HIV-1 
replication.  RNAi silencing of p14ARF, both transiently and stably, inhibited viral 
replication.  There are a number of potential explanations for these unexpected results.  
p14ARF reportedly interacts with multiple viral or host cell proteins that regulate the 
HIV-1 life cycle, including Tat and MDM2, but these interactions can have opposing 
effects on HIV-1 replication (198, 234).  Therefore it is possible that HIV-1 manipulates 
p14ARF levels to establish a particular cellular environment at different points in its life 
cycle. While the role of HIV-1 modulation of p14ARF in the viral life cycle remains 
unclear, p14ARF can clearly regulate HIV-1 replication in a manner opposite to its 
hypothesized antiviral activity. 
 These data are among only handful of reports directly linking the tumor 
suppressor p14ARF and a specific human pathogen, in this instance HIV-1.  The 
mechanism by which HIV-1 is able to modulate p14ARF protein levels in a wide array of 
cell types remains unknown.  With HIV-1 infection generally decreasing p14ARF 
expression, the virus may be attempting to circumvent the antiviral function(s) of 
p14ARF (73).  However, HIV-1 infection induces p14ARF expression at the heavily 
methylated INK4A/ARF locus in U20S cells, suggesting a possible intricate interaction 
between this host cell protein and HIV-1, which results in the virus modulating p14ARF 
levels to specific levels at different times in the viral life cycle.   
An expanded role for p14ARF outside of tumor surveillance has been recently 
proposed in a number of reports, linking p14ARF to the innate immune response, aging,  
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and cardiovascular disease (73, 158, 165).  A broad search is underway to identify new 
host factors that play a role in viral pathogenesis, or its inhibition.  Human proteins such 
as APOBEC3G, TRIM5, and tetherin have been recently identified as retroviral 
restriction factors of varying efficacy (235-237).  Although it is still too early to predict 
whether p14ARF will interact with a similarly wide number of pathogens, further study 
will determine if this is a new host factor restrictive to retroviral infections, or indeed 
conducive to them.     
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Materials and Methods 
Cell culture. U2OS, H1299, HEK 293T and HeLa TZM-bl cells were cultured in 
Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum, 100 
U/ml penicillin, 100µg of streptomycin and incubated in humidified 5% CO2 at 37°C.  
Peripheral blood mononuclear cells were isolated by gradient centrifugation from HIV-1 
seronegative healthy donor blood according to standard procedures.  CD4+ T cells were 
further purified by positive selection using anti-hCD4 magnetic microbeads and MACS 
column (Miltenyi Biotech), following the manufacturer's protocols.  siRNA duplexes 
were transfected with Oligofectamine (Invitrogen), with a siRNA concentration of 40 
nM. After lentiviral infections, pools of cells were selected using puromycin at 2µg/ml.  
Plasmids, siRNAs, shRNA and viral expression vectors. pLenti-ShGFP, pLenti-ShARF, 
and pLenti-Puro-hARF were generated using Gateway cloning System® (Invitrogen).  
Lentiviruses were produced in HEK 293T cells by transfecting ARF constructs along 
with packaging constructs (pol/gag and VSVG). siRNA sequence for human ARF used 
was AAAUCAGGUAGCGCUUCGAUU. 
Pseudotyped virus production and titration.   Pseudoviruses were made by co-
transfecting exponentially dividing 293T cells with a 1:2 ratio of VSV-G and ∆env NL4-
3 plasmids using the Polyethylenimine (Polysciences, Warrington, PA) transfection 
reagent.  After a change of media next day, viral stocks or infection will be harvested 
24hr & 48hr later and quantified using p24 ELISA. 
HIV-1 infection and p24 ELISA. PHA-stimulated PBMC or purified CD4 T cells PHA-
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stimulated overnight were infected at an MOI of 0.5 with virus stocks of wild-type HIV-1 
or VSV-psuedotyped HIV-1.  HIV-1 infected and uninfected or mock-infected CD4 T 
cells were cultured at 106cells/mL in RPMI 1640 supplemented with 10% FCS and 10 
U/mL recombinant human interleukin-2.  
Determination of viral replication.  To follow HIV-1 replication in infected CD4 T cell 
cultures, cell-free culture supernatants were assayed for HIV-1 p24 gag protein by use of 
an in-house antigen-capture ELISA kit.  Culture supernatants were considered positive 
for HIV-1 when the levels of p24 protein are ~20 pg/mL. A steady increase in p24 
antigen level in cell-free supernatant is indicative of active viral replication.  
Immunoblotting.  Cells were lysed in lysis buffer (20 mM HEPES pH 7.4, 0.5% Triton 
X-100, 2 mM MgCl2, 10µM ZnCl2, 2 mM NEM, 1 mM PMSF, 240mM NaCl) containing 
protease inhibitor tablets and analyzed by SDS-PAGE using 4-12% Bis-Tris Nu-PAGE 
gels (Invitrogen). Antibodies used were as follows: p14ARF (Novus), CtBP2 (BD 
Biosciences), and GAPDH (Advanced Immuno).  
Real-time quantitative PCR. mRNA transcripts for human ARF, and GAPDH were 
analyzed by real-time quantitative reverse transcription-PCR (RQ-PCR) using SYBR 
green (Applied Biosystems, Foster City, CA, USA) and an ABI 7300 (Applied 
Biosystems). Relative amounts of the mRNA transcripts were calculated using the ΔΔCT 
method with GAPDH mRNA as internal references. The primer sets used were ARF 
(sense: 5’--3’, antisense: 5’- -3’), GAPDH primers were sense 5’- 
ATCACCATCTTCCAGGAGCGA-3’ and antisense 5’- GCCAGTGAGCTTCC 
CGTTCA-3’.
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Chapter V 
Discussion and Future Directions 
 
 
 In this thesis, I have demonstrated that a previously identified p53-independent 
target of ARF, CtBP, is a promising and potentially widely relevant therapeutic target in 
human cancer.  I have also contributed to the emerging field of non-tumor suppressor 
functions of ARF, identifying a novel interaction between ARF and the HIV.  The 
relevance of these studies to human disease and our evolving understanding of ARF’s 
cellular functions is discussed below.   
 
Shifting Paradigms in Cancer Therapy 
 Cancer is a collection of related diseases with shared characteristics that in the 
earliest phases of tumor growth include the capability for unlimited self-renewal, 
insensitivity to apoptotic stimuli, and self sustained growth signaling (238).  Further 
growth and spread of tumors requires additional capabilities, including the ability to 
invade surrounding tissues, avoid immune surveillance, and recruit non-cancer cells into 
forming new blood vessels to maintain tumor viability.  
These “hallmarks” of cancer cells are derived from activation of oncogenes and 
inhibition of tumor suppressors has been the guiding principal of the molecular study of 
cancer for thirty years.  Cancer arises from random genetic and epigenetic changes that 
result in clonal proliferation, consistent with an evolutionary selection-driven process.  
Recent genomic studies of human cancer cells have revealed that in addition to high 
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frequency mutation, amplification, or deletion events in genes such as Ras, Myc, p53, 
INK4, Rb, and PI3 kinase, there are hundreds of genes mutated at a low frequency in 
different cancers that likely contribute to tumorigenesis. In this way, cancer cells behave 
as genetically related, but distinct, quasi species, not unlike mutation-prone viruses.   
 Attempts to improve cancer therapy by targeting these frequently mutated 
oncogenes has had mixed results, with receptor tyrosine kinase inhibitors (TKIs) being 
the best example.  TKI’s have shown efficacy in a number of different cancers, but drug 
resistance through mutation of drug binding sites, or upregulation of alternative 
pathways, has limited their success.   The phenomenon of cellular functions not targeted  
for mutation, but necessary for tumor survival, collectively referred to as non-oncogene 
addition (NOA) by Elledge and colleagues (239), presents a different philosophical 
approach to the next generation of targeted cancer therapies.  Most of these processes are 
involved in surviving different stresses, such as metabolic, oxidative, proteotoxic, and 
DNA damage.  DNA damaging agents have long been the main stay of chemotherapy, as 
they push cancer cells beyond their capacity to survive or repair the genomic insult.  
Recently developed drugs based on the same concept include inhibitors of heat shock 
proteins and the proteasome, working through not yet fully elucidated mechanisms.  
 
CtBP as a therapeutic target in human cancer 
 Against this background of philosophical shifts in the approach to developing new 
cancer treatments,  I have characterized CtBP as a novel therapeutic target in human 
cancer.  The evidence for a role of CtBP in human cancer is growing.  CtBP has been 
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shown to regulate processes important for oncogenesis, tumor maintenance, and 
progression/metastasis (141). No reports, to date, demonstrate cancer-associated 
mutations in any of the CtBP genes. More likely, CtBP is simply over expressed (at the 
protein level) when it is dysregulated in cancer-as was seen in the colorectal tumors 
studied in Chapter II.  Removal of the tumor suppressor (ARF) constraints, coupled with 
metabolic stimulation of CtBP activity by the hypoxic tumor micro-environment may be 
sufficient, even in the absence of protein over expression, to promote CtBP’s tumorigenic 
functions.   
 Whether CtBP is a classical oncogene remains unclear, but data to support this 
claim has now been presented by multiple groups.  CtBP expression is increased in both 
sporadic colon adenocarinomas as well as in the adenomas of patients with FAP(150, 
240, 241).   Increased CtBP expression is correlated with the loss of either of two well-
known tumor suppressors, ARF (this thesis) and APC (150, 240, 241).  More importantly, 
disregulation of CtBP expression appears to be an early event in colon carcinogenesis, 
preceding nuclear β–catenin accumulation in both patient samples as well as in a zebra 
fish model (150, 241, 242). Therefore, CtBP appears to be a relevant target in human 
cancer, exhibiting tumorigenic dysregulation both during the development and 
progression of neoplastic disease.   
 In this thesis, I have shown that the CtBP substrate MTOB regulates CtBP 
activities in vivo.  Repression of the specific CtBP gene targets Bik and E-cadherin was 
alleviated with MTOB treatment, coinciding with decreased CtBP occupancy on these 
target promoters and increased gene expression in colon cancer and breast cancer cells, 
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respectively.  MTOB was able to block cell migration in multiple cancer cell lines.  
CtBP2 rescue of MTOB-induced cell death in colon cancer cells was complete, as was 
rescue by RNAi knockdown of the BH3 only protein Bik, supporting the hypothesis that 
MTOB-induced cell death is caused by interfering with CtBP repression of Bik. Another 
BH3-only gene, Noxa, was up regulated by MTOB treatment of breast cancer cells, but 
has not been confirmed as sufficient or necessary for MTOB mediated cell death, 
suggesting CtBP, and by extension, MTOB will act through varied signaling networks in 
different cell lines or tissues.  
 In an effort to validate the usefulness of a CtBP inhibitor in human cancer, I have 
shown that CtBP1/2 protein is over-expressed relative to normal tissue in 64% of resected  
colorectal tumors, likely due to concomitant ARF loss and increased CtBP protein 
stability.  Only a minority of tumors (25%) exhibited low CtBP levels, and in this group  
of tumors, ARF and CtBP expression were inversely correlated in ~80% of specimens. 
Thus, abnormally high levels of CtBP were associated with greater than 50% of colon 
adenocarcinoma specimens, suggesting that a substantial fraction of colon cancers may 
exhibit heightened sensitivity to anti-CtBP therapy. 
 This study of CtBP levels in human tumors has limitations that should be 
addressed in the future.  Western blot analysis makes it difficult to quantify actual 
differences in levels of CtBPs between different tumor samples, or between tumor and 
normal tissue.  The western blot levels represent only a crude average for a particular 
section of tumor versus a particular section of normal tissue, with no histology to confirm 
clean margins of either.  Attempts to perform CtBP and ARF immuno-histochemistry on 
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these samples failed to provide clear and interpretable results (data not shown).  In 
addition, while the inverse correlation between ARF and CtBP levels was very clear and 
statistically significant, correlating CtBP or ARF levels with the aggressiveness of the 
disease did not produce statistically significant results (data not shown).  Analying further 
samples from the UMass Tissue Bank was not possible, because all colo-rectal tumor 
samples were analyzed in the initial study.  In the future, as more of these samples are 
collected, further analysis should be performed to determine the relationship of CtBP 
expression to disease stage.  Short of expanded studies, reanalysis of the current western 
blots by densitometry might reveal a more sensitive comparison of CtBP levels and 
disease severity.   
 The evidence to date suggests that MTOB or other compounds that target CtBP 
are viable candidates for therapeutic development.  MTOB is toxic to a variety of cancer 
cell lines derived from many different tissues (this work and (156)).  MTOB toxicity was 
relatively specific for transformed cells, with early passage mouse embryonic fibroblasts 
showing near complete resistance to the compound, but Myc/Ras transformed (ARF-null) 
MEF’s exhibiting sensitivity to MTOB indistinguishable from the most sensitive human 
cancer cell lines.  MTOB has been evaluated as a methionine supplement in livestock 
feed (206), as well as used in the treatment of uremic patients, without reported toxicity 
(209-211).  The oral doses used in both humans and animals were on the order of 
grams/day, with chicks showing no toxicity after receiving 15g/kg daily (206), suggesting 
the compound is well tolerated by healthy tissues in animals, as well as humans.   
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 The mechanism of MTOB inhibition of CtBP still remains to be elucidated.  
There are three plausible possibilities; product inhibition, enzymatic turnover of NADH, 
or steric/allosteric hindrance of NADH binding.  Product inhibition is a real possibility.  
MTHB, the hydroxy analogue of MTOB and product of CtBP catalysis of MTOB, does 
induce cell death in both HCT116 and MCF7 cells (data not shown).  However, MTHB is 
less cytotoxic in the short term assay, and much less cytotoxic in the long term assays 
than MTOB. MTHB  is used as a methione supplement in a billion dollar annual animal 
feed business, as well as in some enteral preparations for human patients.  This readily 
available animal and patient data combined with MTHB’s ease of synthesis would have 
made it a much better drug candidate than MTOB.  Careful in vitro dehydrogenase assays 
with recombinant CtBP and different CtBP substrates in the presence and absence of 
MTHB would resolve the question of whether product inhibition is as effective for CtBP 
inhibition as the substrate inhibition seen with MTOB alone.   
 CtBP’s enzymatic reduction of MTOB to MTHB causes the conversion of NADH 
to NAD+, which has a greatly reduced affinity for CtBP resulting in reduced CtBP 
dimerization and activity.  Whether CtBP‘s enzyme activity for MTOB is efficient 
enough to lead to stoichiometric conversion of cellular NADH to NAD+ and disruption 
of CtBP oligomerization sufficient to relieve transcriptional repression, is unclear.  There 
are several ways to test this hypothesis.  Hypoxia increases CtBP activity by increasing 
intracellular NADH levels, and thus should increase the amount of MTOB necessary to 
reduce CtBP binding of NADH.  A more direct test would be to determine the ability of 
catalytically inactive CtBP to rescue MTOB toxicity.  The mutant CtBP should be more 
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effective then wild type or endogenous CtBP.  Better still would be transfection of this 
mutant into CtBP null MEF’s that also contain a CtBP repression luciferase reporter.  
Catalytically dead CtBP should be immune to MTOB if NADH turnover is necessary for 
its inhibition, since NADH binding and CtBP functions are unaffected by this mutation.  
Using CtBP’s enzymatic activity as a way to modulate its transcriptional activity would  
allow CtBP substrates to work as negative feedback elements for CtBP function.  No 
such connection has been found between CtBP and either polyamine synthesis or 
methionine salvage, the two pathways MTOB is derived from.  This model, however,  
would not explain why CtBP reduction of MTOB is inhibited at higher concentrations in 
vitro, in the presence of excess NADH.   
 Another possibility that better explains loss of enzymatic activity with increasing 
substrate concentration, is that MTOB in sufficient quantities is able to bind apo-CtBP 
before NADH, and then by steric or allosteric mechanisms, block NADH from binding.  
This was the mechanism proposed by Achouri et al., and has precedent (155).  If removal 
of already bound NADH by enzymatic turn over is not necessary, the catalytically dead 
CtBP should still be sensitive to MTOB, assuming this mutation does not alter MTOB 
binding significantly.  Since NADH binding to CtBP can be detected by monitoring the 
fluorescence of a FRET pair between NADH, but not NAD, and a tryptophan in CtBP, 
the effect of the substrate on NADH affinity could be determined (107).  Going further to 
establish the mechanism of MTOB inhibition of CtBP, oligomerization in the presence of 
substrate could be monitored by a number of techniques.  Concentrations of MTOB that 
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shift CtBP oligomerization will likely be lower then those necessary for complete 
enzymatic inhibition, and would further reconcile in vitro and in vivo observations.   
 While I have demonstrated that CtBP over expression and Bik silencing are 
sufficient to inhibit MTOB induced apoptosis, definitively proving MTOB inhibits CtBP 
activity directly would require additional experiments.  Firstly, a CtBP mutant that 
prevents MTOB binding without impacting CtBP function should be able to render cells 
insensitive to MTOB treatment. Testing this mutant will be difficult, since over 
expression of wild type CtBP is already sufficient to rescue MTOB toxicity, CtBP null or 
depleted cells will be required. CtBP null cells are difficult to acquire, and CtBP 
depletion by siRNA has a quick and deleterious affect on cancer cells, so it may not be 
possible to use cell viability as an output.  Instead, transcriptional reporters may need to 
be used to get reliably quantifiable data, even in the presence of wild type endogenous 
CtBP.  Still more convincing evidence that CtBP is the direct target of MTOB would be 
to identify another similarly structured molecule that binds CtBP more tightly, and is a 
more potent cytotoxic agent.  This compound may be found in libraries of small 
molecules, or designed based on structural knowledge of the CtBP substrate binding site. 
Still, this would be imperfect evidence, but would strongly argue against MTOB 
associated up regulation of CtBP targets being a coincidence and not the result of direct 
inhibition of CtBP by MTOB.   
 Understanding the mechanism of small molecule inhibition of CtBP will be 
important if a high throughput screen for pharmacologically viable agents is to be 
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performed.  Developing simple screens, both in vitro, and in vivo, will allow for quick 
identification and evaluation of lead compounds.  Given the availability of crystal  
structure data for CtBP, design of specific inhibitors in silico may be possible.  This 
effort would be aided by the co-crystallization of CtBP in the presence of MTOB.  
Defining the MTOB binding site, as well as any structural changes induced in the NADH 
binding domain, would be useful in designing new inhibitors.   
 The large-scale production of MTOB is difficult and expensive, though a 
pharmaceutical application may provide incentive enough for commercial interests to 
overcome these hurdles.  Therefore, even in the absence of large-scale synthesis, further 
evaluating MTOB activity in vitro and in vivo would be worthwhile.  I have shown that 
MTOB combined with other chemotherapeutics, particularly cis-platin, can produce 
additive or even synergistc cell death.  Given MTOB’s efficacy in the mouse xenograft as 
a single agent, evaluation of MTOB efficacy in combination with standard chemotherapy 
is the next logical step.  Use of the peritoneal model, as well as subcutaneous xeongraft 
systems will be employed to determine if MTOB in combination with agents used in 
colon cancer therapy, such as oxaliplatin and gemcitabine, can better reduce tumor 
burden and extend survival than single agent therapy.  As part of these studies more 
rigorous determination of pharmacokinetics in the mice will need to be undertaken to 
determine the maximal doses delivered to the tumor, as well as the half life of MTOB in 
treated tissues.  This information will allow for more controlled delivery and dosing of 
MTOB.   Further studies would expand these findings to an orthotopic breast cancer 
xenograft system, injecting human cancer cells into the mammary fat pad.  More 
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importantly, I would like to utilize one or several mouse models of cancer to evaluate 
MTOB’s utility as a chemopreventative agent, as well as its efficacy in inhibiting tumor 
growth in a non immuno-compromised animal. Data from human tumors suggests 
cancer-prone mice deficient in either APC or ARF would be an ideal model for testing 
both chemo-preventative and chemotherapeutic applications of MTOB.   
 Preliminary characterization of MEFs from ArfL46D/ArfL46D knock-in mice 
(mutation disrupts ARF/CtBP interaction) has demonstrated increased proliferation and 
immortalization compared to MEFs from wild type animals (Personal communication, R. 
Kovi).  These cells also exhibit increased migratory behavior.  Future experiments will 
utilize these animals in crosses with other tumor prone animals, especially p53 null mice, 
to determine to what extent ARF regulation of CtBP contributes to tumorigenesis and p53 
independent tumor suppression.  Hopefully a CtBP dependent mouse model of cancer 
will evolve from these studies, providing an ideal system for studying the therapeutic 
utility of MTOB or future CtBP inhibitors in preventing and treating cancer.  If disruption 
of CtBP regulation by a single tumor suppressor is not sufficient to induce tumorigenesis, 
developing mice that over express CtBP in an inducible manner may be required.  Tissue 
specific CtBP over expression in an adolescent or adult mouse, thereby avoiding 
developmental defects, should establish whether CtBP disregulation is sufficient for 
tumorigenesis, or whether preceding genetic insults are required.   
 While the loss of ARF mediated degradation of CtBP should provide a model 
system in which to test CtBP inhibitors such as MTOB, there may be opportunities for 
ARF and MTOB to work together or even synergistically (Figure 5.1).  It is currently 
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unknown whether ARF targets all CtBP molecules, or a specific subset.  If ARF only 
targets active CtBP dimers, bound to target promoters, ARF and MTOB will likely be 
inhibiting the same pool of CtBP and thus will not significantly increase cell death when 
added in combination (Figure 5.1A).   However, if ARF is targeting the larger pool of 
CtBP, then it should shift the dose of MTOB required to inhibit CtBP to lower doses and 
thus enhance MTOB cytotoxicity (Figure 5.1B).  Preliminary experiments combining 
exogenous ARF expression with MTOB treatment have revealed additive effects (data 
not shown), but both are have significant effects alone, and thus there is a narrow window 
in which to observe synergy.  An interesting observation from experiments analyzing 
MTOB’s impact on CtBP expression levels revealed a pattern in which MTOB treatment 
of cells expressing ARF often had a negative impact on CtBP protein levels, while ARF 
deficient cells did not.  These suggest that MTOB may be increasing ARF affinity for 
CtBP, or increasing the pool of CtBP that interacts with ARF (Figure 5.1C).  Further 
exploration of these findings will be needed to confirm the potential impact of MTOB on 
CtBP stability in the presence of its negative regulators, ARF and APC.    
 The role of the ARF-CtBP complex in cancer cell survival and migration is part of 
an emerging story about a greater degree of complexity in ARF’s role in tumor 
suppression both at the molecular and genetic level.  Recent discovery of a missense 
mutation in the CtBP binding region of ARF, R54H, in a pedigree of familial melanoma 
could provide the first potential definitive cases of human cancer caused by disruption of  
the p53 independent activities of ARF (49). As sequencing of tumor samples form 
patients becomes more commonplace, the identification of other ARF mutants is likely. 
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ARF’s role in tumor suppression, both p53 dependent and independent, will remain an 
important area of investigation, as attempts to translate understanding of these pathways 
into therapeutic development move forward in the years to come.   
  
 
 
        
 
 
 
Figure 5.1 Potential Interactions Between ARF and MTOB:  ARF and MTOB have the potential to 
interact in their inhibition of CtBPs.  A. ARF and MTOB could be both inhibiting the same pool of 
CtBP, thus failing to produce a additive or synergistic effect.  B.  ARF reduction of total CtBP levels 
could increase the potency of a given dose of MTOB and resulting in increased cell death then with 
either agent alone.  C.  MTOB inhibition of CtBP may enhance its interaction with ARF, resulting in 
decreased CtBP levels and increased cell death. 
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HIV-Host Interactions as Therapeutic Targets 
 Tens of millions of people are infected world wide with HIV.  As work to find a 
viable vaccine continues, highly active anti-retroviral therapy (HAART) remains the best 
and only therapy for HIV infected patients.  The rapid development of drug resistance 
requires that new inhibitors, and new classes of inhibitors be developed.  Drugs targeting 
the viral protease and reverse transcriptase have long been the mainstays of HIV therapy. 
New classes of inhibitors have been approved recently, targeting virus entry and the 
integrase enzyme responsible for inserting the viral genome into the host cell’s DNA.  
New potential drug targets have been identified in recent years by studying virus-host 
interactions, such as VIF and APOBEC3G, capsid and TRIM5α, and LEDGF and 
integrase.   
 p53 is involved in both HIV induced apoptosis and transcription from the viral 
Long Term Repeat (LTR) (175-177).  p53 also is involved in the reverse transcription 
phase of the HIV life cycle, providing proofreading and drug resistance activity.  Given 
the literature describing a role for p53 in HIV infection, and the data presented here 
showing an interaction between ARF and HIV,  one or more therapeutic targets is likely 
to be uncovered by thoroughly dissecting the ARF-p53 pathway involvement in HIV.  To 
that end, p21/waf1, the downstream target of p53, has been noted to inhibit viral 
replication (194, 243, 244). A strategy to reactivate this pathway using a small molecule 
has also already been vindicated in vitro.    
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ARF and HIV 
 The recent discovery of a role for ARF in the murine innate immune response 
encouraged continuation of initial experiments showing HIV modulation of ARF protein 
levels (73).  I have demonstrated that in transformed human cell lines that express ARF, 
HIV infection results in a rapid down regulation of ARF levels, consistent with ARF 
being targeted as a barrier to infection or some other HIV function.  However, HIV 
infection of a transformed line where ARF is silenced, resulted in de-repression and 
expression of ARF in a delayed time course relative to the other cell lines. This result was 
both consistent and yet puzzling at the same time. Stimulation of ARF expression by viral 
infection would make logical sense if ARF is part of the innate response. However, in 
certain cell lines HIV seems capable of counteracting this induction, likely by post-
translational means, but in the U20S cells ARF induction does not seem to be offset by 
the virus.  The relevance of HIV modulation of ARF to viral infection and replication was 
less clear in light of these results.   
 These experiments have several shortcomings that still need to be addressed.  
ARF levels are modulated by HIV infection differently in different cell lines, with both 
transcriptional and potentially post transcriptional regulation involved further 
experiments are required.  Attempts to ascertain the impact of HIV infection on ARF 
protein stability by inhibition of the proteasome with MG132 (data not shown) did not 
reveal significant rescue of ARF levels in H1299 cells, but proteasome inhibition is also 
known to affect HIV replication, thus making the result difficult to interpret. Also, ARF 
levels were not determined in T-cells from the same donor on more then one occasion, 
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making it difficult truly confirm these results in the same genetic background.  Given that 
HIV impacts ARF mRNA and protein levels, not always in a consistent fashion it will be 
important to more carefully correlate ARF mRNA and protein levels in a model system.  
In addition to CD4 T-cells, ARF’s role in HIV infection of macrophages should be 
investigated as well. 
 The previous literature suggested a role for type I interferon in inducing ARF 
expression during viral infection.  Our attempts to induce ARF with interferon alpha in 
either T-cells or U2OS cells (data not shown) produced no substantive evidence that 
interferon contributes significantly to ARF expression in the absence of viral infection, 
suggesting other factors are necessary or earlier reports are incorrect.  For this reason 
further investigation of the role of interferon in ARF expression was postponed.   
RNAi silencing of ARF was therefore employed in the setting of HIV infection to 
directly understand how ARF modulates HIV replication.  Surprisingly, HIV replication 
was reduced by almost 50% in ARF depleted cells four days after infection, suggesting 
that ARF was contributing to viral replication.  Cell lines stably expressing ARF, or a 
short hairpin RNA targeting ARF, were used to support or refute these results.  In two 
different parent cell lines I found that ARF expression promoted greater HIV replication,  
while ARF knockdown inhibited HIV replication. These results are consistent with the 
initial experiment, suggesting that ARF is essential for optimal viral production in these 
cells.   
 Analysis of ARF protein and RNA levels in primary T-cells from different donors 
however contradict this hypothesis.  ARF expression at the protein level, but more 
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uniformly at the RNA level, was reduced in the setting of HIV infection.  Thus HIV 
clearly modulates ARF levels in both the typical viral host cell, as well as transformed 
cell lines.  Manipulation of ARF levels impacts HIV replication in a directly correlated 
manner. Thus, ARF plays a role in HIV biology that results in enhanced HIV production.     
 Contrary to reports that ARF degrades the essential viral protein Tat in the 
absence of viral infection (234), ARF over-expression in this study increased viral 
replication, while ARF depletion negatively impacted viral production.  The current study 
has established a role for ARF in HIV replication, but the mechanism remains to be 
elucidated.  It is possible that ARF does not directly interact with the virus, but alters the 
cellular environment to a more or less favorable one for replication.  Because the cell 
lines used were of varying p53 status, it is unclear if this functional interaction would 
require ARF’s p53 dependent or independent activities.  Given the existing literature on 
p53’s role in HIV infection, it will be important to determine if ARF stabilization of p53 
is an important part of the ARF-HIV interaction.   
 These studies focused on ARF and HIV both because this virus was the most 
convenient system I had access to, but also because of the multiple points of intersection 
between ARF and HIV in the proteins they interact with and cellular functions they are 
involved.  Since ARF’s anti-viral activity was first elucidated usings other viruses like 
VSV, and there are other important human pathogens that interact with ARF, such as 
EBV or HPV, future studies should be expanded to included other pathogens to 
determine how general or specific ARF’s role in viral infection and human disease truly 
is.   
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 Determining what ARF functions are necessary for modulation of the HIV life 
cycle, as well as understanding whether ARF and HIV gene products directly interact in 
the setting of viral infection, will be important for determining the real function of ARF  
in the host response to HIV infection.  At the time of writing, a panel of mutant ARF 
constructs with a T7 epitope tag were being used to generate stable cell lines to determine 
which domains of ARF are capable of enhancing HIV replication.  In addition,  
immunoprecipitation of the T7 tag in infected cells will be used to look for ARF-HIV 
protein complexes.  These experiments will be critical for two reasons.  First, ARF  
domains have been characterized by the proteins they bind to, with the N-terminus 
important for MDM2 and NPM binding, the C-terminus important for cellular 
localization, and the middle region devoid of other identified binding partners with the 
exception of CtBP.  The panel of mutants includes truncations of all three regions, and 
will quickly identify what ARF networks are involved in the modulation of HIV 
replication.  Second, specific pull down of different ARF constructs could identify novel 
HIV-host protein physical interactions.  Determining if ARF directly interacts with Tat, 
Vif, Rev, or other HIV proteins would allow for the design of further mechanistic 
experiments.  Given the large number of potential interactions between ARF and HIV, 
the two could possibly be interacting through an extended network, without any direct 
contact.  This possibility requires that future work first narrow down the relevant domain 
and interacting partners of ARF that are necessary for modulation of HIV activity.   
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What is it that ARF is trying to do?  
 In chapter one of this thesis, the high rate of mutation in both exon1β and exon 2 
of ARF was observed as unique.  Recent insights into the evolution and specificity of 
intrinsic anti-retroviral proteins suggest that ARF’s mutation rate may be due to selective 
pressure from an unknown pathogen or pathogens (2-4, 245, 246).  Both ARF exons have 
undergone a high rate of mutation between murine and human evolution (12).  The ARF 
reading frame of exon 2 exhibits one of the highest rates of non-synonymous change in 
the human genome, while the INK4A reading frame exhibits a conversely high rate of  
synonymous changes, leaving the amino acid sequence of p16INK4a more conserved 
between species.  These mutation rates are highly incongruent with those of the known 
interacting partners of both ARF and p16INK4a.  The authors of this study proposed two 
hypotheses to explain such a high rate of mutation. First, that ARF is undergoing a 
diversifying selection, while INK4A is undergoing a purifying selection.  Second, that 
ARF is undergoing a purifying selection but only requires the conservation of relatively 
few amino acids to maintain functionality.  They chose the latter as more likely, failing to 
see what selective pressure could be driving ARF to diversify.  I would suggest that 
identification of a role for ARF in the innate immune response, coupled with its 
unusually high rate of mutation, make ARF an excellent candidate for a viral restriction 
factor.   
 Evolutionary analysis of the primate retroviral restriction factors APOBEC3 and 
TRIM5 revealed significant rates of non-synonymous change, and evidence of positive 
selection (2, 3).  In the case of TRIM5, the region under selection was localized to a small 
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fragment of the SPRY domain, and determined to be the source of specificity in 
retrovirus restriction.  While the actual biochemical function of the ARF amino acids 
encoded by exon 2 has not been determined, and with only a few reports definitively 
attributing functions or interactions to this domain, its evolutionary conservation despite a 
high rate of mutation suggests this domain serves some non-dispensable role.   
Determination of whether this domain interacts with drivers of selection such as 
retroviruses, endogenous retroviruses, or transposable elements, will shed light on the  
asymmertry of the locus’ evolution, as well as a previously unidentified role in protecting 
the genome from external and internal threats.  ARF, as a highly positively charged 
protein, has been suggested to interact with nucleic acids or even lipids.  This property of 
ARF must be considered in any search for interactions with the aforementioned targets, 
as ARF could interact with pathogens at the RNA or DNA level. At least in exon1β, the 
rate of mutation has slowed greatly in primates, suggesting that the offending pathogen 
may already have been selected against.  Further investigation into ARF’s role in the 
cellular and organismal response to pathogens is definitely warranted.   
 In conclusion, the data presented in this thesis further our understanding of ARF’s 
contribution to human cancer and other diseases.  The p53 independent target of ARF, 
CtBP, is up-regulated in human tumors.  Novel use of CtBP’s substrate MTOB as an 
inhibitor of its transcriptional repressor function was able to induce cancer cell death in 
vitro and in vivo.  Thus, I have provided evidence that a p53 independent target of ARF is 
a valid therapeutic target in human cancer.  I have also shown that the recently defined 
anti-viral activity of ARF may contribute to the cellular response to HIV infection. 
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Modulation of ARF impacts HIV replication by an unknown mechanism.   Whether this 
response is an effective barrier to viral infection, or co-opted in service of viral 
replication remains to be determined.  Combined, these studies add to a growing body of 
work demonstrating a significant role for ARF in human disease.   
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